



Vaccines and Global Health: The Week in Review
2 October 2021 :: Issue 626
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 23,000 entries.

Comments and suggestions should be directed to

*David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org*

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.

Contents [click on link below to move to associated content]

- A. Milestones :: Perspectives :: Featured Journal Content
- B. Emergencies
- C. [WHO; CDC \[U.S., Africa, China\]](#)
- D. [Announcements](#)
- E. [Journal Watch](#)

Milestones :: Perspectives :: Research

:::::
:::::

Strategic Advisory Group of Experts on Immunization (SAGE) - October 2021

4 – 8 October 2021 Virtual Meeting

This meeting for the Strategic Advisory Group of Experts on Immunization (SAGE) will be held from Monday 4 to Thursday 7 October 2021 inclusive. Friday 8 October 2021 is a closed session.

Agenda and meeting information: [SAGE Yellow Book for October 2021](#)

Presentations made during the meeting will be made available online once the meeting has concluded.

SESSIONS [selected topic areas]

- Global and regional reports
- IA2030
- Polio
- COVID-19 vaccines
- Malaria
- Influenza
- Behavioural and social drivers of vaccine uptake
- Hepatitis E

:::::
:::::

Gavi Board meets to discuss routine immunisation, COVAX's 2022 strategy

29 September 2021

::: The Gavi Board met yesterday to discuss the impact of the pandemic on routine immunisation and how COVAX can best support countries' efforts to control the pandemic, as part of a broader consultative process to develop the 2022 COVAX strategy

::: Items covered during the meeting included the resilience of routine immunisation in Gavi-supported countries, the Vaccine Alliance's effort to reach the estimated 12.4 million "zero-dose children" in Gavi-supported countries that do not have access to the most basic life-saving immunisation services, coverage ambitions for COVAX as well as support for delivery in COVAX AMC countries

::: José Manuel Barroso, Board Chair: "Gavi's ambitions have never been greater than they are today: in 2022, the Vaccine Alliance will not only seek to extend its core work on routine immunisation, including reaching millions of zero-dose children, but also play a lead role in COVAX, the largest and most complex roll out of vaccines in history. This Board meeting provided an invaluable opportunity to take stock on both areas of activities as they increasingly converge on the same goal: ensuring that the most vulnerable are able to access life-saving vaccines and the benefits they bring."

[Excerpts]

... Gavi and its Alliance partners UNICEF and WHO continue to help prepare countries for this rapid scale up. At its June meeting the Gavi Board approved new funding of US\$ 799 million to support the delivery of COVAX-funded doses in lower income economies and humanitarian zones over the next two years. The funding comes in addition to a previously approved envelope of US\$ 150 million in delivery support. A significant portion of this funding is being distributed rapidly and on an accelerated timeline

to meet countries' urgent vaccine rollout-related needs, for example rolling out ultra-cold chain infrastructure in time for the arrival of mRNA vaccines.

"As the global solution designed around equitable access to COVID-19 vaccines, COVAX's strategy will continue to adapt as the pandemic evolves." said Dr Seth Berkley, CEO of Gavi. "For many countries, COVAX is one of the primary sources of supply of COVID-19 vaccines, and we must ensure we best serve their needs. As we embark on our most intense period for deliveries yet, COVAX will also continue to focus on strengthening in-country vaccine deployment and even closer coordination with partners such as the African Union. COVAX will also need to focus further on protecting routine immunisation programmes and explore opportunities for integration with Gavi's core strategy, with its particular focus on marginalised and missed communities"...

Gavi progress report shows resilience in childhood vaccinations despite impact of COVID-19 pandemic

29 September 2021

:: In the face of a global pandemic, routine and childhood vaccination has held relatively strong, Gavi's latest Annual Progress Report shows, with routine immunisations dropping 4 percentage points over the course of 2020

:: While lower than 2019, vaccination rates in 2020 were characterised by a significant drop in March to May followed by a strong rebound, which is a testament to the valiant work of governments and health care workers in lower-income countries

Latest statistics show there are now 13.7 million "zero-dose" children in the 68 Gavi-supported countries receiving no immunisations, many of whom live in marginalised communities in remote rural areas, urban slums or conflict settings

[Download the full report here](#)

::::::

::::::

NIAID issues new awards to fund "pan-coronavirus" vaccines

September 28, 2021 — *The awards are intended to fuel vaccine research for a diverse family of coronaviruses, with a primary focus on potential pandemic-causing coronaviruses, such as SARS-CoV-2.*

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded **approximately \$36.3 million to three academic institutions to conduct research to develop vaccines to protect against multiple types of coronaviruses and viral variants.** The awards are intended to fuel vaccine research for a diverse family of coronaviruses, with a primary focus on potential pandemic-causing coronaviruses, such as SARS-CoV-2.

"The available COVID-19 vaccines have proven to be remarkably effective at protecting against severe disease and death," said NIAID Director Anthony S. Fauci, M.D. "These new awards are designed to look ahead and prepare for the next generation of coronaviruses with pandemic potential."

The new awards are funded by NIAID's Division of Microbiology and Infectious Diseases and its Division of Allergy, Immunology, and Transplantation through the Emergency Awards Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program Projects. The notice was issued in November 2020 while many SARS-CoV-2 vaccines were still under development because a critical need remained for prophylactic vaccines offering broad protective immunity against other coronaviruses,

such as Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV).

The awards are designed to fund multidisciplinary teams at each institution to conduct research focused on incorporating understanding of coronavirus virology and immunology, immunogen design, and innovative vaccine and adjuvant platforms and technologies to discover, design, and develop pan-coronavirus vaccine candidates that provide broad protective immunity to multiple coronavirus strains. Specific programs will address coronavirus diversity and infectious potential in humans, include innovative immunogen design and vaccine platforms, and approaches to elicit potent and durable pan-coronavirus immunity, and evaluate vaccine candidates in preclinical models. The awardees are expected to be flexible in the response to emerging knowledge about SARS-CoV-2 immune responses and infection and factor in new information as vaccines candidates are developed. Additional awards are expected to be issued under the NOSI in 2022 to support pan-coronavirus vaccine research at more institutions...

A key goal of the initiative is to develop multivalent vaccine platforms and strategies suitable for use in vulnerable populations and to understand vaccine-induced responses and efficacy related to a person's age or sex.

:::::
:::::
:::::

COVID - PHEIC

Editor's Note:

As is obvious to all, the sheer volume of strategic announcements, regulatory actions, country program decisions, commentary, and, indeed, misinformation around COVID response continues at extraordinary levels. Our weekly digest strives to present a coherent and comprehensive snapshot, but cannot be exhaustive. If you recognize a missed strategic development, a new source of rigorous analysis, or an insight/commentary that would benefit our common understanding, please advise me...we will review all suggestions and consider them for inclusion in a subsequent edition:
david.r.curry@ge2p2global.org

We are seeking access to modelling which engages scenarios and articulates imperatives around a COVID-19 pandemic end-game through at least a 2025 horizon. We assess that WHO must be conducting or contracting for such modeling – or should recognize an imperative to be doing so in its global health governance role. If we have missed such modeling in progress, we would be delighted to be advised of it and will include it in our coverage.

:::::

COVID Vaccines – OCHA::: HDX

COVID-19 Data Explorer: Global Humanitarian Operations

COVID-19 Vaccine Roll-out

Oct 1, 2021 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

Global COVID-19 Figures: 233M total confirmed cases; 4.8M total confirmed deaths

Global vaccines administered: 6.27B

Number of Countries: 29 [29 week ago]

COVAX Allocations Round 4-6 (Number of Doses): 120M [120M week ago]

COVAX Delivered (Number of Doses): 95M [93M week ago]

Other Delivered (Number of Doses): 140M [140M week ago]

Total Delivered (Number of Doses): 240M [230M week ago]

Total Administered (Number of Doses): 220M [210M week ago]

:::::::
::::::

World Bank Vaccine Operations Portal


<https://www.worldbank.org/en/who-we-are/news/coronavirus-covid19/world-bank-support-for-country-access-to-covid-19-vaccines>


*As of September 30, 2021, the **World Bank approved operations to support vaccine rollout in 61 countries amounting to \$5.8 billion. See the latest project financing, project documents and procurement information in the list below.** More information will be shared here as it becomes available.*

:::::::
::::::

Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]

A joint initiative from the International Monetary Fund, World Bank Group, World Health Organization, and World Trade Organization to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries. Website accessed **2 Oct 2021:** <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).





Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Weekly Epidemiological and Operational updates

Last update: 2 Oct 2021

Confirmed cases ::	233 503 524	[230 418 451 week ago]
Confirmed deaths ::	4 777 503	[4 724 876 week ago]
Vaccine doses administered:	6 143 369 655	[5 874 934 542 week ago]



[Weekly epidemiological update on COVID-19 - 28 September 2021](#)

Overview


Globally, the numbers of weekly COVID-19 cases and deaths continued to decline. Over 3.3 million new cases and over 55 000 new deaths were reported during the week of 20 – 26 September 2021, decreases of 10% as compared to the previous week for both cases and deaths. The largest decrease in new weekly cases was reported from the Eastern Mediterranean Region (17%), followed by the Western Pacific Region (15%), the Region of the Americas (14%), the African Region (12%) and the South-East Asia Region (10%); while weekly cases in the European Region were similar to the previous week. The cumulative number of confirmed cases reported globally is now over 231 million and the cumulative number of deaths is more than 4.7 million.

In this edition, two special focus updates are provided on:

:: Approaches to determining waning COVID-19 vaccine effectiveness

:: SARS-CoV-2 Variants of Concern (VOCs) Alpha, Beta, Gamma and Delta which includes updates on the geographic distribution of VOCs

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 26 September 2021**



Summary of the COVID-19 Weekly Operational Update

The Weekly Operational Update (WOU) is a report provided by the COVID-19 Strategic Preparedness and Response Plan (SPRP) monitoring and evaluation team which aims to update on the ongoing global progress against the COVID-19 SPRP 2021 framework.

In this week's edition of the COVID-19 Weekly Operational Update, published on 28 September, highlights of country-level actions and WHO support to countries include:

- Delivering 2 million syringes for Sri Lanka's COVID-19 vaccination drive
- Shipment of WHO life-saving medical supplies to Kabul, Afghanistan with support from Qatar
- WHO logistics hub airlifts largest single shipment of humanitarian cargo to Ethiopia
- WHO/Europe and Germany support children with disabilities in Belarus
- Rebooting COVID-19 response strategy and measures in Cambodia
- Expanding capacity for Integrated Disease Surveillance and Response (IDSR) in the African Region
- External Quality Assessment for laboratories testing for SARS-CoV-2
- Testing Rapid Response Mobile Laboratories (RRML) deployment procedures and minimum standards in first virtual tabletop (V-TTX) exercise for RRML/GOARN
- Connecting countries to share experiences and learnings from their COVID-19 vaccine roll-out using the mini-cPIE (COVID-19 vaccination Intra-Action Review) process
- Progress on a subset of indicators from the SPRP 2021 Monitoring and Evaluation Framework
- Updates on WHO's financing to support countries in SPRP 2021 implementation and provision of critical supplies.



Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 19 August 2021

For 23 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date

[Full scale view available at title line above]

Vaccines		Guidance Document 29 September 2021							
----------	--	--	--	--	--	--	--	--	--

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

1.	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
1.	Pfizer BIONTECH BioNTech Manufacturing GmbH	BNT162b2/COMIRNATY Tozinameran (INN)	EMA	Nucleoside modified mRNA	✓	✓	✓	Finalized: Additional sites: - Baxter Oncology GmbH Germany (DP) - Novartis Switzerland - Mibelle (Dermapharma) Germany (DP) - Delpharm, Saint-Remy FRANCE (DP) - Shell life extension: 09 months at -70 to -90°C	31/12/2020
								Diluent suppliers: - Pfizer Perth, Australia Fresenius Kabi, USA	18/06/2021
2.	AstraZeneca AB	AZD1222 Vaxzevria	EMA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized: Additional sites: - SK-Catalent - Wuxi (DS) - Chemo Spain - Amlyin Ohio US (DP)	16 April 2021
3.	AstraZeneca AB	AZD1222 Vaxzevria	MFDS KOREA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
4.		AZD1222 Vaxzevria	Japan MHLW/PMDA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized Additional site	09 July 2021 TBC
5.		AZD1222 Vaxzevria	Australia TGA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized Additional site: Thailand	09 July 2021 TBC
6.	Serum Institute of India Pvt. Ltd.	Covishield (ChAdOx1_nCoV-19)	DCGI	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
7.	Janssen Infectious Diseases & Vaccines Janssen-Cilag International NV	Ad26.COV2.S	EMA	Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein	✓	✓	✓	Core data finalized (US+NL sites)	12 March 2021
							Additional sites: - Merck, Durham, UK (DS) - Merck, West Point/PA (DP)	Finalized - Aspen RSA (DP) - Catalent Agnani Italy (DP) - Future submission - Future submission	-2 June 2021 -02 July 2021 - As submitted - As submitted

Vaccines		Guidance Document 29 September 2021							
----------	--	--	--	--	--	--	--	--	--

8.	moderna Moderna Biotech	mRNA-1273	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)		✓	✓	Finalized	30 April 2021
			USFDA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	✓	✓	Finalized Moderna ix. Norwood (DS) - Catalent Indiana, LLC (DP) - Lonza Biologics, Inc. Portsmouth, USA (DS) - Baxter, Bloomington, USA (DP)	06 August 2021
9.	Sinopharm / BIBP ¹ Beijing Institute of Biological Products Co., Ltd. (BIBP)	SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	Finalized 2 and 5 dose presentation (new manufacturing site)	07 May 2021 TBC
10.	SINOVAC Sinovac Life Sciences Co., Ltd. Sinovac Life Sciences Co., Ltd.	COVID-19 Vaccine (Vero Cell), Inactivated/Coronavac TM	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	Finalized 2 dose presentation	01 June 2021 30 September 2021
11.	THE GANAYEA IMMUNOTHERAPY CENTER	Sputnik V	Russian NRA	Human Adenovirus Vector-based Covid-19 vaccine	Additional information submitted	Several meetings have been and continue to be held.	"Rolling" submission incomplete.	On hold, awaiting completion of rolling submission	Anticipated date will be set once all data is submitted and follow-up of inspection observations completed.
12.	BHARAT BIOTECH Bharat Biotech, India	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)/COVAXIN	DCGI	Whole-Virion Inactivated Vero Cell	✓	✓	Rolling data started 06 July 2021	Ongoing	October 2021
13.	Sinopharm / WIBP ² CanSinoBio	Inactivated SARS-CoV-2 Vaccine (Vero Cell)	NMPA	Inactivated, produced in Vero cells	✓	✓	Rolling data started 23 July 2021	Ongoing	To be confirmed (TBC)
14.	康希诺生物 CanSinoBio	Ad5-nCoV	NMPA	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	✓	✓	Rolling data started 09 August 2021	Ongoing	TBC
15.	NOVAVAX	NVX-CoV2373/Covovax	EMA	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M TM adjuvant.	✓	✓	Rolling data starting in August 2021	Ongoing	TBC
16.	SANOFI	CoV2 preS dTM-AS03 vaccine	EMA	Recombinant, adjuvanted	✓		Rolling data started 30 July 2021	Ongoing	TBC
17.	SERUM INSTITUTE OF INDIA PVT. LTD. Cytos Biopharmaceuticals	NVX-CoV2373/Covovax	DCGI	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M TM adjuvant.	✓	10 August 2021	Rolling data starting in August 2021	Ongoing	TBC
18.	Clover Biopharmaceuticals	SCB-2019	NMPA	Novel recombinant SARS-CoV-2 Spike (S)-Trimer fusion protein	✓	✓	Rolling data starting 20 September	Ongoing	TBC
19.	CUREVAC Kurevac	Zorecimeran (INN) concentrate and solvent for dispersion for injection; Company code: CVNCoV/CV07050101	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	Planned for Q4 of 2021, at request of the applicant.			
20.	Vector State Research Centre of Virology and Biotechnology	EpiVacCorona	Russian NRA	Peptide antigen	Letter received not EOI, Reply sent on 15/01/2021				

Vaccines							Guidance Document 29 September 2021
21.	Zhifei Longcom, China	Recombinant Novel Coronavirus Vaccine (CHO Cell)	NMPA	Recombinant protein subunit	Response to 2 nd EOI sent 29 Jan 2021. Additional information requested.		
22.	IMBCAMS, China	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	NMPA	Inactivated	Not accepted, still under initial development		
23.	BioCubaFarma - Cuba	Soberana 01, Soberana 02, Soberana Plus Abdala	CECMED	SARS-CoV-2 spike protein conjugated chemically to meningococcal B or tetanus toxoid or A	Awaiting information on strategy and timelines for submission.		

1. Beijing Institute of Biological Products Co-Ltd
2. Wuhan Institute of Biological Products Co Ltd

* Dossier Submission dates: more than one date is possible because of the rolling submission approach. Dossier is accepted after screening of received submission.

**Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant; 4. Risk-benefit decision 5. Final decision made

*** Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors' questions are submitted.

COVID Vaccine Developer/Manufacturer Announcements

[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

AstraZeneca

Press Releases - No new digest announcements identified

BioCubaFarma – Cuba

Últimas Noticias - [Website not responding at inquiry; receiving 403-Forbidden]

CanSinoBIO

News - [Website not responding at inquiry]

Clover Biopharmaceuticals - China

News - No new digest announcements identified

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified

Gamaleya National Center

Latest News and Events - No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China

Home - No new digest announcements identified

Janssen/JNJ

Press Releases

Sep 29, 2021 United States

[Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus \(RSV\) Vaccine in Older Adults](#)

Positive Phase 2b data supporting further evaluation will be presented at IDWeek 2021

Moderna

Press Releases

October 1, 2021

[Joint Statement from Moderna and Takeda](#)

STATEMENT REGARDING Moderna COVID-19 Vaccine Recall Investigation Report – October 2021

Takeda and Moderna today published a report of the investigation prompted by the observation of foreign particles in unpunctured vials from a single lot of Moderna's COVID-19 vaccine distributed in

Japan by Takeda. The lot was suspended on August 26, 2021, JST and voluntarily recalled on September 2, 2021, JST. Two other lots manufactured in the same series were included in the suspension and voluntary recall as a precautionary measure...

September 30, 2021

Moderna to Invest in New Science Center in Cambridge, MA

462,000 square foot state-of-the-art building targeting LEED Zero certification and designed to be the most sustainable commercial lab building in Cambridge

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 30, 2021-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it is investing in a new science center, known as the Moderna Science Center, at 325 Binney Street in Cambridge, Massachusetts to create a purpose-built space to support the Company's next chapter of discovery....

Novavax

Press Releases - No new digest announcements identified

Pfizer

Recent Press Releases

09.29.2021

Positive Top-line Results of Pfizer's Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released

09.28.2021

Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate

09.28.2021

Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age

Formal submission to request Emergency Use Authorization to follow in the coming weeks

...The Companies announced positive topline results from the pivotal trial on September 20, 2021. In the trial, which included 2,268 participants 5 to <12 years of age, the vaccine demonstrated a favorable safety profile and elicited robust neutralizing antibody responses using a two-dose regimen of 10 µg doses...

09.27.2021

Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program

09.27.2021

Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults

Sanofi Pasteur

Press Releases

September 28 2021

Press releases

Sanofi to focus its COVID-19 development efforts on the recombinant vaccine candidate

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA.

Taking into account public health needs and given sufficient mRNA COVID-19 vaccines supply can be expected going forward, **Sanofi has decided not to pursue the development of its COVID-19 mRNA candidate into a Phase 3 clinical study and will focus on completing the final development steps of its COVID-19 recombinant vaccine, developed in partnership with GSK.**

Building on its positive results, the company will focus its mRNA resources in its newly created mRNA Center of Excellence to address future pandemics and other infectious diseases and therapeutics where there is a strong unmet need.

September 28 2021

Press releases

[Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate](#)

:: High seroconversion across the three dosages tested and comparable tolerability to other unmodified mRNA COVID-19 vaccines

:: Now accelerating transformation of acquired platform to modified mRNA and targeting a modified quadrivalent flu mRNA vaccine in the clinic in 2022

September 27 2021

Press releases

[New research presented at IDWeek 2021 reinforces Sanofi's robust vaccines pipeline and commitment to advancing public health protection](#)

[Enrollment begins for Sanofi and GSK's Phase 3 efficacy trial of COVID-19 vaccine candidate in Nepal, led by IVI](#)

Sept. 28, 2021

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases - No new digest announcements identified

Vector State Research Centre of Virology and Biotechnology

Home - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

GSK

Press releases for media

28 September 2021 FDA grants Priority Review to ViiV Healthcare's New Drug Application for cabotegravir long-acting for prevention of HIV

28 September 2021 ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals

Enrollment begins for Sanofi and GSK's Phase 3 efficacy trial of COVID-19 vaccine candidate in Nepal, led by IVI

Sept. 28, 2021

...International Vaccine Institute (IVI) will lead the clinical trial in Nepal to assess the safety, efficacy and immunogenicity of an adjuvanted recombinant-protein COVID-19 vaccine candidate. Phase 3 international clinical trial includes volunteers from several countries, including sites in the US, Asia, Africa and Latin America...

Merck

News releases

Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study

:: At the Interim Analysis, 7.3 Percent of Patients Who Received Molnupiravir Were Hospitalized Through Day 29, Compared With 14.1 Percent of Placebo-Treated Patients Who were Hospitalized or Died
:: Merck Plans to Seek Emergency Use Authorization in the U.S. as Soon as Possible and to Submit Applications to Regulatory Agencies Worldwide
:: If Authorized, Molnupiravir Could be the First Oral Antiviral Medicine for COVID-19
October 1, 2021

SK Biosciences

Press releases - No new digest announcements identified

::::::

::::::

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 2 Oct 2021

An overview of information collected from publicly announced bilateral and multilateral supply agreements [agreements view since last week's edition]



24

vaccines approved for use by at least one national regulatory authority¹



8

vaccines in WHO's Emergency Use Listing



19.4bn

doses secured globally



\$2 - \$37

reported vaccine price range per dose



5.09bn

doses COVAX has secured, optioned, or received as donations



321.8M

doses shipped through COVAX to 144 countries

No new bilateral deals reported since 17 Sep 2021.



Duke – Launch and Scale Speedometer

The Race for Global COVID-19 Vaccine Equity

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution

[accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)

[See our COVID Vaccine Manufacturing research](#)



[See our COVID Vaccine Donations & Exports research](#)

Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged.

Donut charts are ordered by proportion of pledged donations shipped.

Country Category:
Top 10 Donating Countries




Data updated on October 1st 2021.



Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.


Dashboard on Vaccine Equity [accessed 2 Oct 2021]: <https://data.undp.org/vaccine-equity/>
See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)



Our World in Data

Coronavirus (COVID-19) Vaccinations [Accessed 2 Oct 2021]


- :: [45.5%](#) of the world population has received at least one dose of a COVID-19 vaccine.
- :: [6.3 billion doses](#) have been administered globally, and [27.33 million](#) are now administered each day.
- :: Only [2.3%](#) of people in low-income countries have received at least one dose.



Daily COVID-19 vaccine doses administered per 100 people, Oct 1, 2021

Shown is the rolling 7-day average per 100 people in the total population. For vaccines that require multiple doses, each individual dose is counted.


Our World
in Data



COVID-19 vaccine doses administered per 100 people, Oct 1, 2021

For vaccines that require multiple doses, each individual dose is counted. As the same person may receive more than one dose, the number of doses per 100 people can be higher than 100.

Our World
in Data



:::::
:::::

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

:::::

Vaccines and Related Biological Products Advisory Committee- FDA

<https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee>

Vaccines and Related Biological Products Advisory Committee October 14-15, 2021 Meeting Announcement

Agenda

...Under Topic 1, the committee will meet in open session to discuss the Emergency Use Authorization (EUA) of the ModernaTX Inc. COVID-19 vaccine for the administration of an additional dose, or “booster” dose, following completion of the primary series, to individuals 18 years of age and older. On October 15, 2021, under Topic II, the committee will meet in open session to discuss the Emergency Use Authorization (EUA) of the Janssen Biotech Inc. COVID-19 vaccine for the administration of an additional dose, or “booster” dose, to individuals 18 years of age and older.

:::::

White House [U.S.]

Briefing Room – Selected Major COVID Announcements

Statement by President Joe Biden on 700,000 American Deaths from COVID-19

October 02, 2021 • Statements and Releases

Press Briefing by White House COVID-19 Response Team and Public Health Officials

October 01, 2021 • Press Briefings

Press Briefing by White House COVID-19 Response Team and Public Health Officials

September 28, 2021 • Press Briefings

President Biden Announces Intent to Nominate Dr. John N. Nkengasong as Ambassador-at-Large and Coordinator of United States Government Activities to Combat HIV/AIDS Globally

September 27, 2021 • Statements and Releases

Remarks by President Biden While Receiving a COVID-19 Booster Shot

September 27, 2021 • Speeches and Remarks

:::::
:::::

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases

News: EMA welcomes new Head of International Affairs (new)

Last updated: 01/10/2021

EMA is pleased to announce the appointment of Martin Harvey Allchurch as its new head of International Affairs as of 1 October 2021.

Martin Harvey Allchurch brings a wealth of EMA and international experience to this role, having worked in a number of management positions at the Agency, as well as at Unitaid, the World Health Organisation-hosted partnership for access to innovative healthcare in low- and middle-income countries...

News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC)

27-30 September 2021 (new)

PRAC, Last updated: 01/10/2021

...PRAC assessment of rare cases of venous thromboembolism with COVID-19 Vaccine Janssen

The PRAC has concluded that there is a possible link to rare cases of venous thromboembolism (VTE) with COVID-19 Vaccine Janssen...

...The PRAC has now reviewed new evidence from the study described above, as well as new evidence from another large clinical study. In this second study, there was no increase in venous thromboembolic events among individuals who received COVID-19 Vaccine Janssen. The PRAC also reviewed evidence from the post marketing setting - that is data gathered while the vaccine is used in the context of vaccination campaigns. When taking all evidence into account, the committee concluded that there is a reasonable possibility that rare cases of VTE are linked to vaccination with COVID-19 Vaccine Janssen.

The committee is therefore recommending listing VTE as a rare side effect of COVID-19 Vaccine Janssen in the product information, together with a warning to raise awareness among healthcare professionals and people taking the vaccine, especially those who may have an increased risk of VTE...

News: Transatlantic Taskforce continues international fight against antimicrobial resistance (new)

Last updated: 30/09/2021

News: EMA implements new measures to minimise animal testing during medicines development (new)

Last updated: 29/09/2021

::::::

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

Latest Updates

Publication

Rapid Risk Assessment: Assessing SARS-CoV-2 circulation, variants of concern, non-pharmaceutical interventions and vaccine rollout in the EU/EEA, 16th update

Risk assessment

30 Sep 2021

Since its emergence in March 2021, the B.1.617.2 (Delta) variant of concern (VOC) has rapidly become predominant across the European Union/European Economic Area (EU/EEA). More than 99% of newly reported cases are attributed to this variant. The Delta variant has demonstrated a significant

transmission advantage relative to previously circulating SARS-CoV-2 strains. However, full vaccination remains protective against severe outcomes such as hospitalisation, admission to intensive care and death. Currently available vaccines have played a crucial role in limiting viral circulation and in particular, limiting the impact of infections by the Delta variant.

Despite the fact that over 565 million vaccine doses have been administered in the EU/EEA so far, only 61.1% (range: 18.4–79.4%) of the total population in the EU/EEA have been fully vaccinated to date. The total population includes children and adolescents for whom the vaccine is not available or who may not be included in national target groups yet. There is considerable inter-country and sub-national variation in vaccine uptake, resulting in large proportions of the EU/EEA population remaining susceptible to SARS-CoV-2 infection.

Modelling scenarios that consider vaccination coverage, vaccine effectiveness, natural immunity and population contact rates—in the context of continued Delta circulation—indicate that the potential burden of disease risk in the EU/EEA from the Delta variant is high between now to the end of November, unless vaccination coverage can be increased rapidly in the total population in the next few weeks.

News

[High risk of autumn surge in COVID-19 cases and deaths in countries with insufficient vaccination coverage, warns ECDC](#)

News story - 30 Sep 2021

EU/EEA countries that have not yet achieved high enough COVID-19 vaccination coverage in their total populations, which are planning to relax non-pharmaceutical interventions during the next two weeks, run a high risk of experiencing a significant surge of cases, hospitalisations and mortality from now until the end of November. This is indicated by a new SARS-CoV-2 Rapid Risk Assessment published today by the European Centre for Disease Prevention and Control (ECDC).



European Centre for Disease Prevention and Control

COVID-19 Vaccine Tracker

Cumulative uptake of at least one dose among adults (18+) in EU/EEA	Cumulative uptake of full vaccination among adults (18+) in EU/EEA
79.3%	73.5%

Accessed 2 Oct 2021

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

Press release 2 October 2021

EU Humanitarian Air Bridge delivers life-saving medical aid to Afghanistan

Press release 1 October 2021

Code of Practice on disinformation: Commission welcomes new prospective signatories and calls for strong and timely revision

The topic of disinformation remains high on the Commission's agenda. Eight new prospective signatories joined the revision process of the Code of Practice on disinformation during the latest signatories Assembly meeting yesterday.

Press release 28 September 2021

European Health Union: Towards a reform of EU's pharmaceutical legislation

Today, as part of its work to create a future-proof and crisis-resilient regulatory framework for the pharmaceutical sector, the Commission has published a public consultation on the revision of the EU's pharmaceutical legislation.

:::::
:::::

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment



Africa CDC Vaccine Dashboard

Africa Vaccinated

Vaccine Administered (Total)	(79.15% of supply)
Vaccine Administered (1 Dose)	(6.67% of population)
Vaccination Completed	(4.30% of population)

Total of Supply Administered



Vaccines received from COVAX

49
Countries

Vaccines received bilaterally

47
Countries

Vaccines received from AVATT

31
Countries

Accesses 2 Oct 2021. Full scale, interactive dashboard available at:
<https://africacdc.org/covid-19-vaccination/>

Fifteen African countries hit 10% COVID-19 vaccination goal

30 September 2021 WHO AFRO

Brazzaville – Fifteen African countries—nearly a third of the continent's 54 nations—have fully vaccinated 10% of their people against COVID-19.

The global goal of fully vaccinating 10% of every country's population by 30 September was set in May by the World Health Assembly, the world's highest health policy-setting body. Almost 90% of high income-countries have met this target.

Seychelles and Mauritius have fully vaccinated over 60% of their populations, Morocco 48% and Tunisia, Comoros and Cape Verde over 20%. Most of the African countries that have met the goal have relatively small populations and 40% are small island developing states.

All these countries have enjoyed sufficient supplies of vaccines, and many could access doses from separate sources in addition to those delivered through the COVAX Facility, the global platform to ensure equitable access to vaccines. Half of the 52 African countries that have received COVID-19 vaccines have fully vaccinated just 2% or less of their populations.

"The latest data shows modest gains but there is still a long way to go to reach the WHO target of fully vaccinating 40% of the population by the end of the year. Shipments are increasing but opaque delivery plans are still the number one nuisance that hold Africa back," said Dr Richard Mihigo, Immunization and Vaccines Development Programme Coordinator for the World Health Organization (WHO) Regional Office for Africa...

:::::
:::::

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

A clinical study of the combination of AstraZeneca and Sputnik Light vaccines in Azerbaijan shows strong neutralizing antibodies growth in the majority of participants

Press release, 27.09.2021

:::::
:::::

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :
02 October 2021, 08:00
IST (GMT+5:30)

(↑↓ Status change since
yesterday)

Active (0.81%)

273889 (1335↓)

Discharged (97.86%)

33068599 (25455↑)

Deaths (1.33%)

448573 (234↑)

COVID-19 Vaccination
as on : 02 October
2021, 08:00 IST
(GMT+5:30)

Total Vaccination : 89,74,81,554 (69,33,838↑)

Latest Updates

29.09.2021

National Guidelines for Safe Dental Practice During Covid-19 pandemic

Government of India – Press Information Bureau

Latest Press Releases

COVID-19 Vaccination Update - Day 260

India's cumulative vaccination coverage crosses 90 crore landmark milestone

More than 65 lakh Vaccine doses administered today till 7 pm

Posted On: 02 OCT 2021 9:30PM by PIB Delhi

India's COVID-19 vaccination coverage has crossed 90 Crore landmark milestone (90,42,59,810) today. More than 65 lakh (65,27,196) Vaccine Doses have been administered till 7 pm today. The daily vaccination tally is expected to increase with the compilation of the final reports for the day by late tonight.

Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

Press Releases

No new digest content identified

:::::::
:::::::

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

No new digest content identified. See China CDC below for additional announcements.

:::::::
:::::::
:::::::

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

<https://polioeradication.org/polio-today/polio-now/this-week/>

Polio this week as of 29 September 2021

:: The September edition of Polio News with the latest news, programme and case updates is now available [here](#).

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):

- :: Guinea: one cVDPV2 positive environmental sample
- :: Madagascar: two cVDPV1 cases
- :: Mauritania: two cVDPV2 positive environmental samples
- :: Senegal: one cVDPV2 case and three cVDPV2 positive environmental samples

::::::

Event - Eradicating Polio: What more Is Needed?

WFPHA - World Federation of Public Health Associations

Sep 22, 2021

Polio cases have fallen 99.9% since 1988. In 2020 Africa was certified polio free by the World Health Organization. However, polio will remain a key public health concern until such time as there are no wild... **On October 12, 2021**, at 10:00 – 11:00 (CEST), "Eradicating Polio: What more Is Needed?" webinar will be held to focus on the barriers, challenges and leverages to reach every child and eradicate polio globally. [Register](#)

::::::

::::::

WHO/OCHA Emergencies

Editor's Note:

WHO has apparently reorganized and fundamentally shifted how it judges and tracks "emergencies". We found no announcement of descriptive information to share and present the webpage structure as encountered below. Obviously, the dates associated with some of these emergencies suggest that this is an archival platform as well as a current emergencies resource.

Health emergencies list - WHO

"The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences."

[Crisis in Tigray, Ethiopia](#) *[Last apparent update: 5 Aug 2021]*

[Ebola outbreak, Democratic Republic of the Congo, 2021](#) *[Last apparent update: 17 Aug 2021]*

[Ebola outbreak outbreak, N'Zerekore, Guinea, 2021](#) *[Last apparent update: 17 Aug 2021]*

[Coronavirus disease \(COVID-19\) pandemic](#) *[See COVID above]*

[Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020](#)

[Last apparent update: 17 Aug 2021]

[**Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020**](#) [Last apparent update: 17 Aug 2021]

[**Ebola outbreak, Democratic Republic of the Congo, 2018**](#) [Last apparent update: 24 July 2018]

[**Yemen crisis**](#) [Last apparent update: 12 February 2021]

[**Syria crisis**](#) [Last apparent update: 18 June 2021]

[**Somalia crisis**](#) [Last apparent update: 24 March 2018]

[**Nigeria crisis**](#) [Last apparent update: 9 May 2018]

[**Ebola outbreak, Democratic Republic of the Congo, 2017**](#) [Last apparent update: 17 Aug 2021]

[**Zika virus disease outbreak, 2015-2016**](#) [Last apparent update: 24 Jan 2020]

[**Ebola outbreak: West Africa, 2014-2016**](#) [Last apparent update: 17 Aug 2021]

[**Iraq crisis**](#) [Last apparent update: 9 Jan 2008]

[**South Sudan crisis**](#) [Last apparent update: 23 Sep 2020]

[**Avian influenza A \(H7N9\) virus outbreak**](#) [Last apparent update: 13 September 2021]

[**Middle East respiratory syndrome \(MERS-CoV\) outbreak**](#) [Last apparent update: 8 July 2019]

[**Influenza A \(H1N1\) virus, 2009-2010 pandemic**](#) [Last apparent update: 10 Aug 2010]

::::::

[**UN OCHA – Current Emergencies**](#)

Current Corporate Emergencies

Afghanistan

No new digest content identified

Northern Ethiopia

[**Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 30 Sept 2021**](#)

HIGHLIGHTS

- Malnutrition among pregnant and lactating women screened during the week is unprecedently high with 79% of some 15,000 women diagnosed with acute malnutrition in Tigray.
- Huge price hike due to severe shortages of essential commodities in Tigray.
- Some 126,000 people received food (half the number of people reached the prior week), of whom 52% received only 2 kg of pulses due to reduced supplies.
- Between 23 and 25 September, 33 trucks with food commodities entered Tigray, and 35 empty trucks returned to Semera from Mekelle to carry more food stock back into the region.
- Humanitarian partners continue to scale up response in Afar and Amhara regions.

:::::
:::::

WHO & Regional Offices [to 2 Oct 2021]

<https://www.who.int/>

1 October 2021

News release

WHO prioritizes access to diabetes and cancer treatments in new Essential Medicines Lists

1 October 2021

Departmental news

Case study: Pilot implementation in Nigeria and Zambia, SBI COVID-19 data collection tool

30 September 2021

Departmental news

INSPIRE Adaptation and Scale Up Guide

29 September 2021

Departmental news

Countries commit to climate resilient, low carbon health systems ahead of COP26

28 September 2021

Departmental news

Papua New Guinea steps up efforts to eliminate lymphatic filariasis

28 September 2021

News release

WHO and partners call for urgent action on meningitis

28 September 2021

Departmental news

Safe abortion in the context of COVID-19: partnership, dialogue and digital innovation

27 September 2021

Departmental news

WHO sets up an Advisory Group on TB Diagnostics and Laboratory Strengthening

:::::

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: [Fifteen African countries hit 10% COVID-19 vaccination goal](#) 30 September 2021

:: [Scaling up genomic sequencing in Africa](#) 30 September 2021

WHO Region of the Americas PAHO

No new digest content identified

WHO South-East Asia Region SEARO

:: 1 October 2021 Improve COVID-19 immunization coverage of elderly population: WHO

WHO European Region EURO

:: Launch of the Pan-European Mental Health Coalition 30-09-2021

:: 7 COVID-19 hospitals in Armenia receive modern X-ray equipment 27-09-2021

WHO Eastern Mediterranean Region EMRO

:: A fighting chance for children born prematurely in Yemen 29 September 2021

:: WHO and System Staff College open pandemic leadership programme materials to public 28 September 2021

WHO Western Pacific Region

:: Action needed to increase patient safety and improve maternal and newborn care 28 September 2021

::::::

New WHO Publications [Selected]

<https://www.who.int/publications/i>

Selected Titles

1 October 2021

Annex to Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed

Overview

This document is an update of a guidance published on 12 July 2021, after the review of new scientific evidence on transmission of SARS-CoV-2 variants of concern (VOC). It contains updated recommendations on the use of masks and respirators for health workers providing care to suspected or confirmed COVID-19.

30 September 2021

WHO Model List of Essential Medicines for Children - 8th list, 2021

30 September 2021

Executive summary: the selection and use of essential medicines 2021: report of the 23rd WHO Expert Committee on the selection and use of essential medicines

... *Section 19.3 Vaccines*

This section was reviewed by the Secretariat for consistency and full alignment with the latest WHO recommendations for routine immunization (September 2020). No changes to the current vaccine listings on the EML and EMLc were required.

30 September 2021

WHO model list of essential medicines - 22nd list, 2021

Overview

The core list presents a list of minimum medicine needs for a basic health-care system, listing the most efficacious, safe and cost-effective medicines for priority conditions. Priority conditions are selected on

the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment.

29 September 2021

Neurology and COVID-19: Scientific brief, 29 September 2021

29 September 2021

COVID-19 disease in children and adolescents: Scientific brief, 29 September 2021

27 September 2021

Measuring health inequalities in the context of sustainable development goals

:::::
:::::

CDC/ACIP [U.S.] [to 2 Oct 2021]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases, Announcements

CDC Statement on Pregnancy Health Advisory

Wednesday, September 29, 2021

Today, CDC issued an urgent health advisory to increase COVID-19 vaccination among people who are pregnant, recently pregnant (including those who are lactating), who are trying to become pregnant now, or who might become pregnant in the future to prevent serious illness, deaths, and adverse pregnancy outcomes.

The CDC health advisory strongly recommends COVID-19 vaccination either before or during pregnancy because the benefits of vaccination for both pregnant persons and their fetus or infant outweigh known or potential risks. Additionally, the advisory calls on health departments and clinicians to educate pregnant people on the benefits of vaccination and the safety of recommended vaccines.

According to CDC data, only 31 percent of pregnant people have been vaccinated against COVID-19 and vaccination rates vary markedly by race and ethnicity. Vaccination coverage is highest among Asian people who are pregnant (45.7 percent), but lower among Hispanic or Latino pregnant people (25 percent), and lowest among Black pregnant people (15.6 percent)...

Next ACIP Meetings

No registration is required to watch the webcast.

:: October 20-21, 2021 - No agenda posted at 2 Oct 2021

MMWR News Synopsis Friday, October 1, 2021

Selected Content

:: Progress Toward Poliomyelitis Eradication — Pakistan, January 2020–July 2021

:: Disparities in COVID-19 Vaccination Status, Intent, and Perceived Access for Noninstitutionalized Adults, by Disability Status — National Immunization Survey Adult COVID Module, United States, May 30–June 26, 2021

:: Association Between K–12 School Mask Policies and School-Associated COVID-19 Outbreaks — Maricopa and Pima Counties, Arizona, July–August 2021

:: [COVID-19–Related School Closures and Learning Modality Changes — United States, August 1–September 17, 2021](#)

:: [Pediatric COVID-19 Cases in Counties With and Without School Mask Requirements — United States, July 1–September 4, 2021](#)

:: [Safety Monitoring of an Additional Dose of COVID-19 Vaccine — United States, August 12–September 19, 2021](#)

[Coronavirus Disease 2019 \(COVID-19\)- CDC](#)

Approximately 25 announcements/reports/data summaries.

:::::

:::::

Africa CDC [to 2 Oct 2021]

<http://www.africacdc.org/>

News

[Statement on UK travel restrictions, September 24, 2021](#)

28 September 2021

The Africa Centres for Disease Control and Prevention (Africa CDC), a Specialised Technical Institution of the African Union, noted with deep concern the planned changes to international travel rules in the context of the COVID-19 pandemic, communicated by the Government of the United Kingdom (U.K), which will be enforced starting at 4:00 am on Monday 4th October 2021.

According to U.K government [sources](#)¹, the new rules will discriminate between the recipients of COVID-19 vaccines not based on the vaccine received but on the region in which these vaccines were received. Travellers whose vaccination is not recognised based on where they received the vaccines, including but not limited to the African Union Member States, will have to take additional measures resulting in a significant financial and social burden. These extra measures include two additional tests (pre-departure and “day 8 test” and quarantine for ten days. The sources provide no further explanation and rational behind this new rules.

The restrictions will therefore apply to persons having received vaccines through the COVAX programme, of which the U.K is one of the largest supporters, with over USD 700 million as well as 80 million vaccine doses pledged to the programme. The COVAX supplies constitute almost half of the COVID-19 vaccines supplied to the African continent to date.

We are deeply concerned that policies and rules such as this carry a risk of deepening vaccines hesitancy across Africa and creates distrust in the community...

:::::

:::::

China CDC <http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 2 Oct 2021]

<http://en.nhc.gov.cn/>

News

[Oct 2: Daily briefing on novel coronavirus cases in China](#)

On Oct 1, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 41 new cases of confirmed infections.

China stresses strict COVID-19 prevention during National Day holiday

2021-09-30

Booster shot plans being drawn up

2021-09-30

China is accelerating the formulation of policies and implementation guidelines for COVID-19 vaccine booster shots for key groups of people as the risk of infection from imported novel coronavirus variants remains high, a health official said on Wednesday.

Cui Gang, an official at the National Health Commission, said the commission will guide local governments to give booster shots first to people who have been fully vaccinated for six months and work in high-risk areas including airports, ports, border checkpoints and hospitals, as well as people over the age of 60...

COVID chronicle outlining WHO mission published

2021-09-30

China published a chronicle on Wednesday of its work facilitating a WHO-organized mission to study the origins of the novel coronavirus, offering a detailed look at the open and transparent way it was conducted.

The chronicle starts in July last year, when the World Health Organization and China began laying the groundwork for deepening understanding of the novel coronavirus' origins and reached an agreement on an initial phase of the study in Wuhan, Hubei province.

It ends in late March, after a joint report was released to the public and international and Chinese members of the team held briefings about the investigation results...

National Medical Products Administration – PRC [to 2 Oct 2021]

<http://english.nmpa.gov.cn/news.html>

News

Over 2.206 bln COVID-19 vaccine doses administered in China

2021-09-30

Over 2.206 billion doses of COVID-19 vaccine had been administered in China as of Tuesday, data from the National Health Commission showed on Sept 29.

First China-led international standard for COVID-19 prevention and control medical devices

2021-09-30

CCDC Weekly - Weekly Reports: Current Volume (3)

2021-10-01 / No. 40

[View PDF of this issue](#)

No new digest content identified.

:::::
:::::
:::::

Organization Announcements

Editor's Note:

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group [to 2 Oct 2021]

<https://alleninstitute.org/what-we-do/frontiers-group/news-press/>

News

No new digest content identified.

BARDA – U.S. Department of HHS [to 2 Oct 2021]

<https://www.phe.gov/about/barda/Pages/default.aspx>

News

No new digest content identified.

BMGF - Gates Foundation [to 2 Oct 2021]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 2 Oct 2021]

<https://www.gatesmri.org/>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

No new digest content identified.

CARB-X [to 2 Oct 2021]

<https://carb-x.org/>

News

07.29.2021 |

[**CARB-X celebrates five years of progress in early-stage product development against antibiotic-resistant bacteria**](#)

CARB-X, a global non-profit partnership led by Boston University, is celebrating five years of progress in funding and supporting the development of innovative products targeting antibiotic-resistant bacteria. Since it was founded in July 2016, CARB-X has invested \$361 million in non-dilutive funding to develop innovative therapeutics including new classes of antibiotics and non-traditional agents, vaccines and other preventatives such as CRISPR-phage, microbiome-modifying agents and antibodies, and rapid diagnostics.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 2 Oct 2021]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: Past weekly editions and posting of all segments of **Vaccines and Global Health: The Week in Review** are [available here](#).

:: **[NEW] Informed Consent: A Monthly Review – October 2021** is now posted [here](#)

CEPI – Coalition for Epidemic Preparedness Innovations [to 2 Oct 2021]

<http://cepi.net/>

Latest News

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [to 2 Oct 2021]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 2 Oct 2021]

<https://dukeghic.org/>

Our Blog

[**What the Latest Global COVID-19 Summit Achieved \(and missed\)**](#)

WEEKLY COVID VACCINE RESEARCH UPDATE Friday, September 24, 2021

EDCTP [to 2 Oct 2021]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 2 Oct 2021]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 2 Oct 2021]

<http://www.euvaccine.eu/>

Latest News

No new digest content identified.

Fondation Merieux [to 2 Oct 2021]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 2 Oct 2021]

<https://www.gavi.org/>

News releases [See Milestones above for detail]

Gavi statement on the report of the independent commission on sexual exploitation and abuse

30 September 2021

Gavi Board meets to discuss routine immunisation, COVAX's 2022 strategy

29 September 2021

Gavi progress report shows resilience in childhood vaccinations despite impact of COVID-19 pandemic

29 September 2021

GHIT Fund [to 2 Oct 2021]

<https://www.ghitfund.org/newsroom/press>

GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that

No new digest content identified.

Global Fund [to 2 Oct 2021]

<https://www.theglobalfund.org/en/news/>

News & Stories

News

Global Fund Welcomes Netherlands New Contribution to the Global Fight Against COVID-19

01 October 2021

The Global Fund to Fight AIDS, Tuberculosis and Malaria welcomed the decision by the Netherlands to contribute an additional €15 million to the Global Fund's COVID-19 Response Mechanism, on top of the €12 million committed in April 2021.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 2 Oct 2021]

<https://www.glopid-r.org/news/>

22/09/2021

COVID-19: Advances and Remaining Challenges international conference opens September 29

Institut Pasteur will hold this international conference in collaboration with Inserm ANRS – Maladies infectieuses émergentes from September 29 to October 1, 2021. COVID-19 experts from around the

globe will attend the event which will be broadcast live in English and held under the high patronage of the French President.

Leading researchers and clinicians will present the progress made and remaining challenges in virology, clinical presentations and management, epidemiology, and vaccinology for COVID-19. Topics to be covered include:

- Viral entry and replication/neutralization
- Viral persistence and Long COVID
- Patient management and future treatments
- Evaluation of impact of interventions
- Children and SARS-CoV-2 transmission and control
- Vaccine regimens and effectiveness
- Why and how should we get the planet vaccinated?

[Learn more & register](#)

Hilleman Laboratories [to 2 Oct 2021]

<http://www.hillemanlabs.org/>

Website reports "under maintenance" at inquiry

Human Vaccines Project [to 2 Oct 2021]

<http://www.humanvaccinesproject.org/>

News

HVP COVID Report

Sep 30, 2021

[Salim Abdool Karim: The Broken System of Vaccine Distribution](#)

Director of the Centre for the AIDS Program of Research, South Africa

Professor of Global Health, Columbia University

HVP Editor Kristen Jill Abboud recently spoke about the distribution of COVID vaccines in South Africa with Salim Abdool Karim, a clinical infectious disease epidemiologist who heads the Centre for the AIDS Program of Research in South Africa (CAPRISA) and is a Professor of Global Health at Columbia University in New York City. Karim also serves on the Lancet COVID-19 Commission and is the former chair of the South African Ministerial Advisory Committee on COVID-19. We discussed the early setbacks in the rollout of vaccines in South Africa and the lessons this pandemic offers for future global vaccine distribution.

IAVI [to 2 Oct 2021]

<https://www.iavi.org/newsroom>

Latest News

September 30, 2021

[IAVI applauds Biden Administration's intent to nominate John Nkengasong as head of PEPFAR](#)

Nkengasong was a founding leader of PEPFAR and has served on IAVI's board since 2018.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICRC [to 2 Oct 2021]

<https://www.icrc.org/en/whats-new>

Selected News Releases, Statements, Reports

IHL App 2.0: International humanitarian law and more in your pocket

01-10-2021 | Article

DigitHarium Month #7: Biometrics and Humanitarian Protection

For the seventh DigitHarium month, we looked at how we can make biometric data work for humanitarian organizations: what they are, how they function, what advantages they present, and what mitigation measures we need to consider to make them safer to

01-10-2021 | Article

International Day for the Total Elimination of Nuclear Weapons Statement, September 2021

Mr President of the General Assembly, Mr Secretary-General, Distinguished Colleagues, I am pleased to mark this important event to commemorate the International Day for the Total Elimination of Nuclear Weapons.

30-09-2021 | Article

Joint Statement by the UN Resident and Humanitarian Coordinator and the Heads of ICRC, OCHA, UNICEF, and WHO in Afghanistan

In the meeting, we agreed to collaborate closely together and have committed our organizations to spare no effort in our joint objective to support the existing health system in Afghanistan to ensure all people have access to the healthcare they need

29-09-2021 | Statement

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 2 Oct 2021]

<http://media.ifrc.org/ifrc/news/press-releases/>

Selected Press Releases, Announcements

30/09/2021

COVID-19: IFRC calls for urgent action to tackle vaccine hesitancy in Europe amid increase in violent incidents

Budapest/Geneva, 30 September 2021 – The International Federation of Red Cross and Red Crescent Societies (IFRC) is calling for urgent action to tackle vaccine hesitancy in Europe, where there has been a worrying increase in violent incidents against COVID-19 related health infrastructure and personnel...

In addition, disinformation about vaccines' side effects and potential risks, coupled with the introduction of 'vaccine passes', is sparking anger and violence, which have led to concerning incidents

against medical services, media and the general public in countries including Italy, the Netherlands, the United Kingdom, Poland, Slovenia and France....

30/09/2021

Afghanistan faces collapse of health services and mass hunger

... Speaking from Kabul where he has been on a four-day official visit, Alexander Matheou, IFRC Asia Pacific Director said: "After living through decades of fleeing and fighting, Afghans now face a severe drought which has devastated food production, leaving millions hungry and destitute. We are deeply concerned that Afghanistan faces imminent collapse of health services and worsening hunger if aid and money do not flow into the country within weeks. Health financing has been cut across the country placing ever more demand on Red Crescent teams. Urgent international action is needed to support millions of people with the necessities of life as Afghanistan's looming harsh winter threatens greater misery and hardships."...

28/09/2021

IFRC launches emergency appeal to prepare for and respond to population movements from Afghanistan

Institut Pasteur [to 2 Oct 2021]

<https://www.pasteur.fr/en/press-area>

Press Documents

Press release

21.09.2021

Covid-19: study on the effectiveness of immune memory after mRNA vaccination to recognize variants of SARS-CoV-2

The teams from Henri-Mondor AP-HP hospital and Paris-Est Créteil University, Inserm, CNRS, University of Paris, within the Necker-Enfants Malades Institute, and the Institut Pasteur analyzed the capacity of the immune memory generated after mRNA vaccination to recognize and neutralize SARS-CoV-2 variants.

This work, coordinated by Prof. Matthieu Mahévas, Dr Claude-Agnès Reynaud, Prof. Jean-Claude Weill, Dr Pascal Chappert, Dr Félix Rey and Dr Pierre Bruhns, shows that people vaccinated with a messenger RNA vaccine against SARS-CoV-2 develop defenses against the Beta and Delta variants. Their immune system indeed produces memory cells capable of recognizing and neutralizing these worrisome variants. The results of this study were [published](#) on September 20, 2021 in *Immunity*.

IOM / International Organization for Migration [to 2 Oct 2021]

<http://www.iom.int/press-room/press-releases>

News - Selected

News

30 Sep 2021

UN Agencies Call for Protection Measures and a Comprehensive Regional Approach for Haitians on the Move

ISC / International Science Council [to 2 Oct 2021]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

News Press

Action for Afghan scientists and scholars

01.10.2021

The InterAcademy Partnership (IAP) and the International Science Council (ISC) express concern for Afghan scholars in Afghanistan and around the world, and call for urgent action to preserve gains made in education and research in Afghanistan in recent decades.

Blog

Science in Exile podcast series launched

30.09.2021

ISC Presents: Science in Exile features interviews with refugee and displaced scientists who share their science, their stories of displacement, and their hopes for the future. In the first episode, available now, Feras Kharrat shares his experiences as a scholar of molecular biomedicine, first in Syria, and now in Italy.

News Press

Gender Equality in Science: Inclusion and Participation of Women in Global Science Organizations

Results of two global surveys show women are still under-represented in world science. New report from the ISC, InterAcademy Partnership and Gender Insite released today.

IVAC [to 2 Oct 2021]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 2 Oct 2021]

<http://www.ivi.int/>

IVI News & Announcements

The International Vaccine Institute, Texas Children's Hospital, and Baylor College of Medicine partner for collaborative vaccine research

Sept. 28, 2021 – SEOUL, South Korea, and HOUSTON, Texas, USA

...The collaboration is envisioned to include: (1) exchange of scientists between institutions; (2) collaborative research in vaccine development; (3) the sharing of scholarly and scientific materials, and (4) steps toward establishing an international collaborating office of IVI in a formal academic relationship with the Section of Pediatric Tropical Medicine in the Department of Pediatrics at Baylor...

Enrollment begins for Sanofi and GSK's Phase 3 efficacy trial of COVID-19 vaccine candidate in Nepal, led by IVI

Sept. 28, 2021

...International Vaccine Institute (IVI) will lead the clinical trial in Nepal to assess the safety, efficacy and immunogenicity of an adjuvanted recombinant-protein COVID-19 vaccine candidate

Phase 3 international clinical trial includes volunteers from several countries, including sites in the US, Asia, Africa and Latin America...

IVI's Statement for the Global COVID-19 Summit: Ending the Pandemic and Building Back Better

... To meet these goals, IVI is partnering with over 2 dozen organizations, from the laboratory through and beyond licensure, to move multiple COVID-19 vaccine candidates from testing to impact providing the kind of evidence that will inform better policy decisions on the use of vaccines and non-pharmacologic interventions...

Johns Hopkins Center for Health Security [to 2 Oct 2021]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News

25 Stakeholder Groups ask Congress to Support the \$16 Billion Funding Level for Pandemic Preparedness Included in the Build Back Better Act Passed by the House Energy and Commerce Committee

September 28, 2021

MSF/Médecins Sans Frontières [to 2 Oct 2021]

<http://www.msf.org/>

Latest [Selected Announcements]

Libya

Medical care resumes in Tripoli detention centres

Project Update 29 Sep 2021

Iraq

Tackling multidrug-resistant tuberculosis, one patient at a time

Project Update 29 Sep 2021

Syria

Northern Syria: Acute water crisis poses serious health risks

Project Update 29 Sep 2021

National Academy of Medicine - USA [to 2 Oct 2021]

<https://nam.edu/programs/>

Selected News/Programs

National Academy of Medicine Releases Video Encouraging Latinx/Latino(a)/Hispanic Americans to Accept the COVID-19 Vaccine

September 28, 2021

Today, the National Academy of Medicine (NAM) released a video encouraging Latinx/Latino(a)/Hispanic Americans to get vaccinated for COVID-19. The video, which features 11 Latinx/Latino(a)/Hispanic members of the NAM, highlights the safety and efficacy of the vaccines, reinforces their integral role in bringing families and communities back together safely, and features personal affirmations from the NAM [...]

National Academy of Sciences - USA [to 2 Oct 2021]

<http://www.nasonline.org/news-and-multimedia/>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 2 Oct 2021]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 2 Oct 2021]

<http://www.nih.gov/news-events/news-releases>

News Releases

NIAID issues new awards to fund “pan-coronavirus” vaccines

September 28, 2021 — The awards are intended to fuel vaccine research for a diverse family of coronaviruses, with a primary focus on potential pandemic-causing coronaviruses, such as SARS-CoV-2. *[See COVID - U.S. above for detail]*

PATH [to 2 Oct 2021]

<https://www.path.org/media-center/>

Press Releases

No new digest content identified.

Sabin Vaccine Institute [to 2 Oct 2021]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

Commentary to the Global COVID-19 Summit: Ending the Pandemic and Building Back Better

September 15, 2021

UNAIDS [to 2 Oct 2021]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

1 October 2021

ArtPositive—art to raise awareness around HIV-related stigma and discrimination

29 September 2021

The first but not the last: Indonesian transgender man fights for recognition

28 September 2021

Launch of advocacy explainers on western Africa model drug law

UNHCR Office of the United Nations High Commissioner for Refugees [to 2 Oct 2021]

<http://www.unhcr.org/en-us/media-centre.html>

Selected News Releases, Announcements

UN agencies call for protection measures and a comprehensive regional approach for Haitians on the move

Joint statement by UNHCR, IOM, UNICEF, OHCHR

30 Sep 2021

Yemeni humanitarian organization wins 2021 UNHCR Nansen Refugee Award

UNHCR, the UN Refugee Agency, announces the winner of its 2021 Nansen Refugee Award. Five regional winners are also announced.

29 Sep 2021

News Comment: UNHCR echoes call for global action to resolve internal displacement

This news comment is attributable to Raouf Mazou, UNHCR's Assistant High Commissioner for Operations

29 Sep 2021

UN: Syrian Refugees in Lebanon Struggle to Survive Amid Worst Socioeconomic Crisis in Decades

29 Sep 2021

UNICEF [to 2 Oct 2021]

<https://www.unicef.org/media/press-releases>

Press Releases, News Notes, Statements [Selected]

Statement

10/01/2021

UNICEF statement on Ethiopia

NEW YORK, 1 October 2021 – “The Ethiopian Government’s decision to expel the UNICEF representative in the country – along with other members of the UN leadership team – is regrettable and alarming.

“UNICEF has been present in Ethiopia for more than 60 years, working to advance and protect the rights of the most vulnerable children. As the humanitarian situation in the country deteriorates – with children bearing its biggest brunt – our work is more urgent than ever. We have full confidence in the teams working on the ground to save children’s lives, guided – as always – by the principles of impartiality, humanity, neutrality and independence. Our programmes will continue. Our one and only priority is to support the children who urgently need our help, wherever they are.”

Press release

09/30/2021

Indonesia: More than 25,000 children orphaned due to COVID-19 since the start of the pandemic

UNICEF and partners call for greater support for families and surviving caregivers to ensure children remain in family-based care.

JAKARTA, 30 September 2021 – Since the start of the pandemic, 25,430 children in Indonesia have lost one or both caregivers due to COVID-19 according to a nationwide mapping by the Ministry of Women Empowerment and Child Protection (MoWECP) and UNICEF.

The mapping finds that the majority of children (57 per cent) have lost a male caregiver, over a third (37 per cent) have lost a female caregiver, and around five per cent have lost both caregivers. Most of the children are currently being looked after by a female caregiver, some by their extended families while 114 children are unaccompanied and are not being cared for by any adult.

The loss of one or both caregivers can have a detrimental impact on the nutrition, growth and development of children and can put them at greater risk of neglect, violence and exploitation – particularly infants and young children from low-income families. Children orphaned or bereft of their caregivers often face adverse consequences, including poverty and institutionalization.

The surviving or alternative caregivers also face additional economic and mental health burdens, which often fall on women and adolescent girls and may put them at increased risk of dropping out of school.

"We continue to monitor responses given to children whose parents died due to COVID-19 from all stakeholders," said I. Gusti Ayu Bintang Darmawati, Minister of Women's Empowerment and Child Protection. "We will make sure that these children are protected, and their rights can be fulfilled."...

Statement

09/30/2021

UN agencies call for protection measures and a comprehensive regional approach for Haitians on the move

Joint statement by UNHCR, IOM, UNICEF, OHCHR

Press release

09/29/2021

EU Humanitarian Airbridge helps deliver 32 tonnes of UNICEF humanitarian supplies to Afghanistan

Remarks

09/29/2021

Remarks by UNICEF Executive Director Henrietta Fore at the launch of the Global Framework for United Nations Support on Syria/Iraq Third Country National Returnees

Unitaid [to 2 Oct 2021]

<https://unitaid.org/>

Featured News

Unitaid statement on molnupiravir as a treatment for mild and moderate COVID-19

Geneva, 1 October 2021 – Unitaid, on behalf of partners in the Access to COVID-19 Tools (ACT) Accelerator, welcomes [today's announcement](#) on molnupiravir, an investigational oral antiviral medicine for treatment of mild and moderate COVID-19. Interim Phase 3 clinical trial results show that molnupiravir significantly reduced the risk of hospitalization or death from COVID-19 by approximately 50 percent when given in the early stages of infection.

"Effective, simple to use, oral treatments that can avert the progression to severe illness are exactly the kind of breakthroughs we need to get the pandemic under control. Deployed alongside vaccines, such medicines could drive down hospitalizations and deaths due to COVID-19," said Dr Philippe Duneton, Executive Director of Unitaid.

Such a treatment could fundamentally change the response to the pandemic, enabling integrated test-and-care strategies when deployed together with appropriate diagnostic tests...

Statement in remembrance of Girindre Beeharry

Geneva, 30 September 2021 – I am deeply saddened by the passing of Girindre Beeharry, who represented the Bill and Melinda Gates Foundation on Unitaid's Board, a position he held for several years. His memory remains very much alive. I would like to pay tribute to his clear-sightedness – the sharpness of his analyses went hand-in-hand with his humanity and his sense of humour. I wish to recognize and celebrate Girindre's commitment to global public health. Through his unwavering dedication, he enabled Unitaid to move forward and find new solutions for people who need access to prevention, diagnostics, and treatments.

On behalf of everyone at Unitaid, our deepest sympathies and our most sincere condolences to Girindre's family and to his daughter in particular.

Dr. Philippe Duneton, Executive Director, Unitaid

Vaccine Equity Cooperative [nee Initiative] [to 2 Oct 2021]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 2 Oct 2021]

<https://www.vaccineacceptance.org/>

Announcements

No new digest content identified.

Vaccine Confidence Project [to 2 Oct 2021]

<http://www.vaccineconfidence.org/>

News, Research and Reports

Coronavirus global impact

Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

Vaccine Education Center – Children's Hospital of Philadelphia [to 2 Oct 2021]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

Feature Article — Guillain-Barré Syndrome (GBS) & Vaccines: The Risks and Recommendations

Published on Sep 14, 2021

Wellcome Trust [to 2 Oct 2021]

<https://wellcome.ac.uk/news>

News and reports

No new digest content identified.

The Wistar Institute [to 2 Oct 2021]
<https://www.wistar.org/news/press-releases>
Press Releases
No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 2 Oct 2021]

<https://www.wfpha.org/>

Latest News

Eradicating Polio: What more Is Needed?

Sep 22, 2021

Polio cases have fallen 99.9% since 1988. In 2020 Africa was certified polio free by the World Health Organization. However, polio will remain a key public health concern until such time as there are no wild... On October 12, 2021, at 10:00 – 11:00 (CEST), "Eradicating Polio: What more Is Needed?" webinar will be held to focus on the barriers, challenges and leverages to reach every child and eradicate polio globally. [Register](#)

World Bank [to 2 Oct 2021]

<http://www.worldbank.org/en/news/all>

Selected News, Announcements

The World Bank Provides US\$ 500 Million to Strengthen Argentina's COVID-19 Vaccination Plan

WASHINGTON D.C., October 1, 2021 – The World Bank Board of Directors today approved a US\$500 million loan to strengthen Argentina's efforts to contain the COVID-19 pandemic. The loan will be used to procure...

Date: October 01, 2021 Type: Press Release

Nigeria Scales Up its COVID-19 Vaccination with New Funding for Vaccine Purchase and Deployment

WASHINGTON, September 30, 2021 — The Government of Nigeria today received approval from The World Bank Board of Directors for a \$400 million credit in additional financing from the International Development...

Date: September 30, 2021 Type: Press Release L

Development in a Time of Upheaval – World Bank Group President

Malpass outlines ways to boost growth, combat reversals in gender equality and human development, address rising inequality and climate change KHARTOUM, Sept. 30, 2021—World Bank Group President David...

Date: September 30, 2021 Type: Press Release

Development in a Time of Upheaval - Positioning Speech by World Bank Group President David Malpass

Watch the full recording of the speech. Thank you, Prime Minister Hamdok for the warm introduction and hospitality. Ladies and gentlemen, it's a great pleasure for me to be speaking today from Africa...

Date: September 30, 2021 Type: Speeches and Transcripts

US\$100 Million to Support COVID-19 Vaccination in Iraq

BAGHDAD, September 28, 2021 — The World Bank has approved a new US\$100 million project to scale up Iraq's health sector response to the COVID-19 pandemic. The Iraq COVID-19 Vaccination Project will...

Date: September 28, 2021 Type: Press Release Language: English

World Customs Organization – WCO [to 2 Oct 2021]

<http://www.wcoomd.org/>

Latest News – Selected Items

01 October 2021

Members of the WCO North of Africa, Near and Middle East (MENA) region discuss challenges and solutions in the cross-border e-commerce environment

World Organisation for Animal Health (OIE) [to 2 Oct 2021]

<https://www.oie.int/en/for-the-media/press-releases/2021/>

Press Releases, Statements

Enhancing veterinary laboratory capacity in COVID-19's wake through the first-ever virtual OIE PVS mission

News

28 September 2021

The COVID-19 pandemic has marked a challenging but breakthrough moment for science, research and society at large. A cornerstone of human and animal health systems, laboratories across the world have seen the continuity of their operations put to the test. Their significant engagement to enhance capacity, to conduct research and to put equipment and expertise at the disposal of the larger health system, often meant that only critical diagnostic laboratory functions were maintained and ramped up, while other types of activities had to take a back seat. Travel restrictions made access to laboratory facilities limited or nearly impossible for external stakeholders, and essential quality assurance activities, such as audits and technical training, became difficult to implement. Among these challenges was the implementation of in-country missions by the World Organisation for Animal Health (OIE).

WTO - World Trade Organisation [to 2 Oct 2021]

http://www.wto.org/english/news_e/news_e.htm

WTO News and Events

No new digest content identified.

::::::

ARM [Alliance for Regenerative Medicine] [to 2 Oct 2021]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 2 Oct 2021]

<https://www.bio.org/press-releases>

Press Releases, Letters, Testimony, Comments [Selected]

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 2 Oct 2021]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 2 Oct 2021]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 2 Oct 2021]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

[African research foundation partners with international pharmaceutical industry to strengthen capacity for health innovation innovation in Africa](#)

28 September 2021, Cape Town/Geneva – [H3D-Foundation \(H3D-F\)](#) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) announced today a three-year partnership to strengthen capacity for health innovation in Africa. The two organizations will combine forces to focus on driving capacity strengthening for drug discovery and development in Africa by scaling existing initiatives and identifying new development opportunities for young and mid-career scientists in the region.

The COVID-19 pandemic has highlighted the urgent need to bolster Africa's ability, including its drug innovation capabilities, to face future health emergencies. Africa only conducts approximately 2 percent of world research on new infections, despite shouldering a quarter of the global disease burden[\[1\]](#). While the continent is better prepared now to contribute to new healthcare threats as they emerge compared to a few decades ago, the disease focus remains narrow and is often not fully aligned with regional priorities. According to H3D-F, a foundation established to reduce barriers for health innovation and actively support African researchers and centers within the field of drug discovery and related sciences, the continent is primed for progress but requires an integrated health innovation ecosystem, investment in robust infrastructure, technology platforms, a critical mass of skilled talent, and job creation.

"The University of Cape Town Holistic Drug Discovery & Development (H3D) centre is the only integrated drug discovery and development platform in Africa. Over the last 10 years, it has proven itself as a platform to develop world class infrastructure, talent, and health innovation that will contribute to improving lives not only in Africa, but all over the world. We are ready to take our work to the next level through partnership and collaboration with key organizations like IFPMA, strengthening capacity far beyond H3D," said Kelly Chibale, Chairman and CEO of H3D-F and Founder and Director of H3D.

Africa now hosts over 250 research sites and 73 vaccine clinical trials, but there are many gaps to fill[2]. For example, less than 10 universities provide vaccinology courses and only two local universities engage in vaccine-related pre-clinical studies[3]. IFPMA's role is to be an anchor partner to provide short- to mid-term support in increasing awareness of H3D-F activities to develop and strengthen the capacity of human resources for health innovation in Africa. It will facilitate networking and visibility across the innovation ecosystem through its membership and offer opportunities for collaboration from drug development to market. Shared aims of the organizations are to call attention to drug innovation and access in the region – key pillars to achieving the sustainable development goals and universal health coverage...

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest content identified.

International Alliance of Patients' Organizations – IAPO [to 2 Oct 2021]

<https://www.iapo.org.uk/news/topic/6>

Press and media [Selected]

No new digest content identified.

PhRMA [to 2 Oct 2021]

<http://www.phrma.org/>

Latest News [Selected]

No new digest content identified.

*

*

*

*

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 12, 2020 Issue 3

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 23, Number 9: E667-756 Sep 2021

<https://journalofethics.ama-assn.org/issue/implantable-material-and-device-regulation>

Implantable Material and Device Regulation

About 10% of Americans will have a device implanted into their bodies during their lifetimes. Fewer than 0.5% of these devices, however, are likely to have been tested in rigorous clinical trials generally regarded as standard by US regulators. Despite looser regulation of materials and devices than for pharmaceuticals, clinician-investigators and the Food and Drug Administration are obligated to balance patient-subjects' safety with demand for patients' timely access to technologies and interventions that might improve or extend their lives. This issue investigates that tension.

[Reviewed earlier]

American Journal of Infection Control

September 2021 Volume 49 Issue 9 p1093-1214

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

September 2021 Volume 61 Issue 3 p311-464

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

September 2021 111(9)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 105 (2021): Issue 2 (Aug 2021)

<https://www.ajtmh.org/view/journals/tpmd/105/2/tpmd.105.issue-2.xml>

[Reviewed earlier]

Annals of Internal Medicine

September 2021 Volume 174, Issue 9

<http://annals.org/aim/issue>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 298 September 2021

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/298/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 2 Oct 2021)

[No new digest content identified]

BMJ Global Health

September 2021 - Volume 6 - 9

<https://gh.bmjjournals.org/content/6/9>

[Reviewed earlier]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 2 Oct 2021)

[Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation](#)

Genetic testing has potential roles in identifying whether an individual would have risk of adverse drug reactions (ADRs) from a particular medicine. Robust cost-effectiveness results on genetic testing would ...

Authors: Saowalak Turongkaravee, Jiraphun Jittikoon, Onwipa Rochanathimoke, Kathleen Boyd, Olivia Wu and Usa Chaikledkaew

Citation: BMC Health Services Research 2021 21:1042

Content type: Research article

Published on: 2 October 2021

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 2 Oct 2021)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 2 Oct 2021)

[Defining ethical challenge\(s\) in healthcare research: a rapid review](#)

Despite its ubiquity in academic research, the phrase 'ethical challenge(s)' appears to lack an agreed definition. A lack of a definition risks introducing confusion or avoidable bias. Conceptual clarity is a ...

Authors: Guy Schofield, Mariana Dittborn, Lucy Ellen Selman and Richard Huxtable

Citation: BMC Medical Ethics 2021 22:135

Content type: Research

Published on: 29 September 2021

[Cross-cultural validation of the IRB Researcher Assessment Tool: Chinese Version](#)

Using an effective method for evaluating Institutional Review Board (IRB) performance is essential for ensuring an IRB's effectiveness, efficiency, and compliance with applicable human research standards and o...

Authors: Xing Liu, Ying Wu, Min Yang, Yang Li, Jessica Hahne, Kaveh Khoshnood, Linda Coleman and Xiaomin Wang

Citation: BMC Medical Ethics 2021 22:133

Content type: Research

Published on: 28 September 2021

COVID-19 underscores the important role of Clinical Ethics Committees in Africa

The COVID-19 pandemic has magnified pre-existing challenges in healthcare in Africa. Long-standing health inequities, embedded in the continent over centuries, have been laid bare and have raised complex ethic...

Authors: Keymanthri Moodley, Siti Mukaumbya Kabanda, Anita Kleinsmidt and Adetayo Emmanuel Obasa

Citation: BMC Medical Ethics 2021 22:131

Content type: Research article

Published on: 25 September 2021

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 2 Oct 2021)

Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections

This study aims to identify the causative strain of SARS-CoV-2 in a cluster of vaccine breakthroughs. Vaccine breakthrough by a highly transmissible SARS-CoV-2 strain is a risk to global public health.

Authors: Timothy Farinholt, Harsha Doddapaneni, Xiang Qin, Vipin Menon, Qingchang Meng, Ginger Metcalf, Hsu Chao, Marie-Claude Gingras, Vasanthi Avadhanula, Paige Farinholt, Charu Agrawal, Donna M. Muzny, Pedro A. Piedra, Richard A. Gibbs and Joseph Petrosino

Citation: BMC Medicine 2021 19:255

Content type: Research article

Published on: 1 October 2021

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 2 Oct 2021)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 2 Oct 2021)

Governance structure affects transboundary disease management under alternative objectives

The development of public health policy is inextricably linked with governance structure. In our increasingly globalized world, human migration and infectious diseases often span multiple

administrative jurisdictions that might have different systems of government and divergent management objectives. However, few studies have considered how the allocation of regulatory authority among jurisdictions can affect disease management outcomes.

Authors: Julie C. Blackwood, Mykhaylo M. Malakhov, Junyan Duan, Jordan J. Pellett, Ishan S. Phadke, Suzanne Lenhart, Charles Sims and Katriona Shea

Citation: BMC Public Health 2021 21:1782

Content type: Research

Published on: 2 October 2021

Patients at high risk for a severe clinical course of COVID-19 — small-area data in support of vaccination and other population-based interventions in Germany

Research has shown that the risk for a severe course of COVID-19 is increased in the elderly population and among patients with chronic conditions. The aim of this study was to provide estimates of the size of...

Authors: Jakob Holstiege, Manas K. Akmatov, Claudia Kohring, Lotte Dammertz, Frank Ng, Thomas Czihal, Dominik von Stillfried and Jörg Bätzing

Citation: BMC Public Health 2021 21:1769

Content type: Research

Published on: 28 September 2021

Population preferences and attitudes towards COVID-19 vaccination: a cross-sectional study from Pakistan

While vaccine development is itself a challenge; ensuring optimal vaccine uptake at population level can present an even more significant challenge. Therefore, this study aimed to assess the Pakistani populati...

Authors: Muhammad Junaid Tahir, Muhammad Saqlain, Waleed Tariq, Summaiya Waheed, Steven H. S. Tan, Sarim Irhas Nasir, Irfan Ullah and Ali Ahmed

Citation: BMC Public Health 2021 21:1759

Content type: Research article

Published on: 26 September 2021

Tolerability of MenACWY-TT vaccination in adolescents in the Netherlands; a cross-sectional study

In 2018, meningococcal ACWY-TT vaccine (MenACWY-TT) was offered to adolescents in the Netherlands within the National Immunization Programme at 14 years of age. A questionnaire study assessed the tolerability ...

Authors: J. M. Kemmeren, L. van Balveren, A. Kant and H. de Melker

Citation: BMC Public Health 2021 21:1752

Content type: Research article

Published on: 26 September 2021

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 2 Oct 2021)

[No new digest content identified]

BMJ Evidence-Based Medicine

October 2021 - Volume 26 - 5

<https://ebm.bmj.com/content/26/5>

[Reviewed earlier]

BMJ Open

September 2021 - Volume 11 - 9

<https://bmjopen.bmj.com/content/11/9>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 99(9); 2021 Sep 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/388476/>

[Reviewed earlier]

Cell

Sep 30, 2021 Volume 184 Issue 20 p5071-5260

<https://www.cell.com/cell/current>

Commentary

[COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants](#)

Muge Cevik, Nathan D. Grubaugh, Akiko Iwasaki, Peter Openshaw

As the SARS-CoV-2 epidemic evolves, new variants continue to emerge. Some highly transmissible variants, such as Delta, also raised concerns about the effectiveness provided by current vaccines. Understanding immunological correlates of protection and how laboratory findings correspond to clinical effectiveness is imperative to shape future vaccination strategies.

Child Care, Health and Development

Volume 47, Issue 5 Pages: 575-731 September 2021

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 110, Issue 3 Pages: 519-825 September 2021

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

June 2021 Volume 43 Issue 6 p917-1134

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 18 Issue 5, October 2021

<https://journals.sagepub.com/toc/ctja/18/5>

Ethics

[Navigating the ethics of remote research data collection](#)

Luke Gelinas, Walker Morrell, Sarah A White, Barbara E Bierer

First Published July 7, 2021; pp. 606–614

COVID-19 has accelerated broad trends already in place toward remote research data collection and monitoring. This move implicates novel ethical and regulatory challenges which have not yet received due attention. Existing work is preliminary and does not seek to identify or grapple with the issues in a rigorous and sophisticated way. Here, we provide a framework for identifying and addressing challenges that we believe can help the research community realize the benefits of remote technologies while preserving ethical ideals and public trust. We organize issues into several distinct categories and provide points to consider in a table that can help facilitate ethical design and review of research studies using remote health instruments.

Design

[Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom](#)

M Estée Török, Benjamin R Underwood, Mark Toshner, Claire Waddington, Emad Sidhom, Katherine Sharrocks, Rachel Bousfield, Charlotte Summers, Caroline Saunders, Zoe McIntyre, Helen Morris, Jo Piper, Gloria Calderon, Sarah Dennis, Tracy Assari, Anita Marguerie de Rotrou, Ashley Shaw, John Bradley, John O'Brien, Robert C Rintoul, Ian Smith, Ed Bullmore, Krishna Chatterjeeon behalf of the Cambridge COVID Vaccine Trial Team

First Published June 22, 2021; pp. 615–621

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 2 Oct 2021]

[No new digest content identified]

Contemporary Clinical Trials

Volume 108 September 2021

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/108/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 4, Issue 4 / August 2021

<https://www.liebertpub.com/toc/crispr/4/4>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 9, issue 3, September 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-3>

[Reviewed earlier]

Current Opinion in Infectious Diseases

August 2021 - Volume 34 - Issue 4

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

Developing World Bioethics

Volume 21, Issue 3 Pages: 97-148 September 2021

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 31, Issue 6, 2021

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 15 - Issue 3 - June 2021

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 45, Issue 4 Pages: 739-995 October 2021

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

EMBO Reports

Volume 22 Issue 9 6 September 2021

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 27, Number 9—September 2021

<http://wwwnc.cdc.gov/eid/>
[Reviewed earlier]

Epidemics

Volume 36 September 2021
<https://www.sciencedirect.com/journal/epidemics/vol/36/suppl/C>
[Reviewed earlier]

Epidemiology and Infection

Volume 149 - 2021
<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>
[Reviewed earlier]

Ethics & Human Research

Volume 43, Issue 5 Pages: 1-44 September–October 2021
<https://onlinelibrary.wiley.com/toc/25782363/current>
[Reviewed earlier]

Ethics & International Affairs

Summer 2021 (35.2) August 2021
<https://www.ethicsandinternationalaffairs.org/2021/spring-2021-35-1/>

The editors of *Ethics & International Affairs* are pleased to present the Summer 2021 issue of the journal! The highlight of this issue is a roundtable organized by Adrian Gallagher on the responsibility to protect in a changing world order. The roundtable contains an introductory essay by Michael Ignatieff and contributions from Adrian Gallagher and Nicholas J. Wheeler; Cristina G. Stefan; Luke Glanville and James Pattison; and Jennifer M. Welsh. Additionally, the issue includes feature articles by Daniele Amoroso and Guglielmo Tamburrini on meaningful human control over weapons systems and Patricia Goff on inclusive trade. It also contains a review essay by Andrea C. Simonelli on climate displacement and justice and book reviews by Reed Bonadonna, Cian O'Driscoll, and Shelley Wilcox.

[Reviewed earlier]

Ethics, Medicine and Public Health

September 2021
<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/18/suppl/C>
[Reviewed earlier]

The European Journal of Public Health

SUPPLEMENT - Volume 31, Issue Supplement_1, July 2021
https://academic.oup.com/eurpub/issue/31/Supplement_1

Supplement: E-Mental-Health: Exploring the Evidence Base and Stakeholders' Perspectives on Internet-Based Interventions for the Prevention of Mental Health Conditions

Mental illness represents an enormous personal, social and societal burden for European citizens¹ calling for the need to expand existing models of mental healthcare delivery. In Europe, the Internet is a key source of health information,² and technology-enhanced (psychological) interventions such as Internet- and mobile-delivered applications ('eHealth³ and 'm-Health⁴) have become increasingly popular and studied. There is already strong evidence of the efficacy of online interventions for the prevention and treatment of several psychological disorders^{5,6} and meta-analyses show effect sizes similar to face-to-face interventions.⁷

Expert Review of Vaccines

Vol 20 (9) 2021

<https://www.tandfonline.com/toc/ierv20/current>

Article

Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2

Divakar Sharma

Pages: 1051-1057

Published online: 06 Aug 2021

Review

A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations

Raunak Parikh, Robyn Widenmaier & Nicolas Lecrenier

Pages: 1065-1075

Published online: 01 Sep 2021

Article

Gap between willingness and behavior in the vaccination against influenza, pneumonia, and herpes zoster among Chinese aged 50–69 years

Xinyue Lu, Jia Lu, Liping Zhang, Kewen Mei, Baichu Guan & Yihan Lu

Pages: 1147-1152

Published online: 21 Jul 2021

Article

Disproportionate COVID-19 vaccine acceptance rate among healthcare professionals on the eve of nationwide vaccine distribution in Bangladesh

A.B.M. Muksudul Alam, Md Anwarul Azim Majumder, Mainul Haque, Fatema Ashraf, Mohib Ullah Khondoker, Saidur Rahman Mashreky, Abrar Wahab, Tosaddeque Hossain Siddiqui, Aftab Uddin, Taufique Joarder, S.M. Moslehuddin Ahmed, Farzana Deeba, Kamrun Nessa, Sayeeda Rahman, Iffat Jahan, Zakirul Islam, Nihad Adnan, Munzur- E-Murshid, Shafiqul Islam, Umme Laila Urmi, Abdullah Yusuf, Nitai Chandra Sarkar, Taslim Sajjad Mallik, A.M. Selim Raza, A.K.M. Daud & Mohammed S. Razzaque

Pages: 1167-1175

Published online: 06 Sep 2021

Article

Understanding COVID-19 vaccine acceptance in Pakistan: an echo of previous immunizations or prospect of change?

Tehniat F Ahmed, Affan Ahmed, Sheharyar Ahmed & Haadi U Ahmed

Pages: 1185-1193

Published online: 17 Aug 2021

Forum for Development Studies

Volume 48, 2021 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 2 Oct 2021]

Research Article metrics

Revised

COVID-19: Identifying countries with indicators of success in responding to the outbreak

[version 2; peer review: 1 approved, 1 approved with reservations]

David S. Kennedy, VK Vu, Hannah Ritchie, Rebecca Bartlein, Oliver Rothschild, Daniel G. Bausch, Max Roser, Anna C. Seale

Peer Reviewers Richard A. Kock; Flavio Codeco Coelho

Funders - Bill and Melinda Gates Foundation, Department of Health & Social Care, Wellcome Trust

LATEST VERSION PUBLISHED 29 Sep 2021

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 2 Oct 2021]

[No new digest content identified]

Global Health Action

Volume 14, Issue 1 (2021)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 9, No. 3 September 30, 2021

<http://www.ghspjournal.org/content/current>

ORIGINAL ARTICLES

Open Access

Applying Adult Learning Best Practices to Design Immunization Training for Health Care Workers in Ghana

Denise Traicoff, Dieula Delissaint Tchoualeu, Joseph Opare, Melissa Wardle, Pamela Quaye, Hardeep S. Sandhu and George Bonsu

Global Health: Science and Practice September 2021, 9(3):487-497; <https://doi.org/10.9745/GHSP-D-21-00090>

Best practices of adult learning were used to develop a training of trainers program for the Ghana Health Service immunization workforce. The program supported translating learning to behavior change, used class time for practice-teaching and action plan development, linked formal instruction with specific activities, and offered follow-up mentorship.

Open Access

Evaluation of the Impact of Immunization Second Year of Life Training Interventions on Health Care Workers in Ghana

Dieula Delissaint Tchoualeu, Bonnie Harvey, Mawuli Nyaku, Joseph Opare, Denise Traicoff, George Bonsu, Pamela Quaye and Hardeep S. Sandhu

Global Health: Science and Practice September 2021, 9(3):498-507; <https://doi.org/10.9745/GHSP-D-21-00091>

Applying performance-based training interventions that follow adult learning principles and include follow-up activities after training may help to solve specific performance problems and improve health care workers' performance in immunization service delivery. These strategies facilitate learning, minimize the forgetting curve for health care workers, and should be considered as a standard practice for future training interventions.

Income Inequalities in Hepatitis B Vaccination and Willingness to Pay Among Women of Reproductive Age in Hanoi, Vietnam

Xuan Thi Thanh Le, Nguyen Thao Thi Nguyen, Huong Thi Le, Toan Thanh Thi Do, Thang Huu Nguyen, Huong Lan Thi Nguyen, Trang Ha Nguyen, Linh Gia Vu, Bach Xuan Tran, Carl A. Latkin, Cyrus S.H. Ho and Roger C.M. Ho

Global Health: Science and Practice September 2021, 9(3):523-531; <https://doi.org/10.9745/GHSP-D-20-00480>

Many countries use a fee-for-service model for hepatitis B vaccination, which amplifies health disparities across socioeconomic statuses and contributes to inequalities in HBV vaccination rates. We examined the role of household income on women's willingness to pay and the amount they are willing to pay for HBV vaccination to identify a more optimized payment scheme and equitable access across all income groups.

Global Legal Monitor – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 2 Oct 2021]

[No new digest content identified]

Global Public Health

Volume 16, Issue 8-9 (2021)

<http://www.tandfonline.com/toc/rgph20/current>

Politics and pandemics

This Special Issue of Global Public Health on Politics & Pandemics brings together 26 articles and commentaries that address diverse aspects of the politics of COVID-19 and related issues. These papers are grouped together in six topical areas: theories and politics of global health, health systems and policies, country responses, social inequalities, social responses, and the politics of science and technology. The goal of the Special Issue is to give readers a sense of the range of topics that have been a focus for research in relation to the COVID-19 pandemic and to provide diverse examples of

how research and analysis on the political dimensions of the pandemic can contribute to confronting the COVID-19 crisis.

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 2 Oct 2021]

COVID-19: Factors associated with psychological distress, fear, and coping strategies among community members across 17 countries

The current pandemic of COVID-19 impacted the psychological wellbeing of populations globally.

Authors: Muhammad Aziz Rahman, Sheikh Mohammed Shariful Islam, Patraporn Tungpunkom, Farhana Sultana, Sheikh M. Alif, Biswajit Banik, Masudus Salehin, Bindu Joseph, Louisa Lam, Mimmie Claudine Watts, Sabria Jihan Khan, Sherief Ghozy, Sek Ying Chair, Wai Tong Chien, Carlos Schönenfeldt-Lecuona, Nashwa El-Khazragy...

Citation: Globalization and Health 2021 17:117

Content type: Research

Published on: 1 October 2021

Health and Human Rights

Volume 23, Issue 1, June 2021

<https://www.hhrjournal.org/volume-23-issue-1-june-2021/>

General Papers

PERSPECTIVE Should COVID-19 Vaccines Authorized for Emergency Use Be Considered "Essential" Medicines?

Maxwell J. Smith, Lisa Forman, Michael Parker, Katrina Perehudoff, Belinda Rawson, and Sharifah Sekalala

Is Mandatory Vaccination for COVID-19 Constitutional under Brazilian Law?

Daniel Wei Liang Wang, Gabriela Moribe, and Ana Luisa Gajardoni de M. Arruda

Virtual Roundtable

Equitable COVID-19 Vaccine Access

Els Torreele and Joseph J. Amon

Health Economics, Policy and Law

Volume 16 - Issue 4 - October 2021

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[New issue; No digest content identified]

Health Policy and Planning

Volume 36, Issue 8, October 2021

<https://academic.oup.com/heapol/issue/36/8>

[Reviewed earlier]

Health Research Policy and Systems
<http://www.health-policy-systems.com/content>
[Accessed 2 Oct 2021]
[Reviewed earlier]

Human Gene Therapy
Volume 32, Issue 17-18 / September 2021
<https://www.liebertpub.com/toc/hum/32/17-18>
Pathways/Interview
[**Gene Therapy, the Immune System, and Vaccine Development: An Interview with Hildegund Ertl**](#)
[Thomas Gallagher](#)
Pages:865–867
Published Online:23 September 2021
<https://doi.org/10.1089/hum.2021.29177.her>

Humanitarian Exchange Magazine
Number 79, May 2021
<https://odihpn.org/magazine/localisation-and-local-humanitarian-action/>
[**Localisation and local humanitarian action**](#)
by HPN October 2020
The theme of this edition of *Humanitarian Exchange* is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies, non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported. Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 17, Issue 10, 2021
<https://www.tandfonline.com/toc/khvi20/current>
[Reviewed earlier]

Immunity [NEW JOURNAL ADDED]
Sep 14, 2021 Volume 54 Issue 9 p1903-2168
[https://www.cell.com/immunity/issue?pii=S1074-7613\(20\)X0010-0](https://www.cell.com/immunity/issue?pii=S1074-7613(20)X0010-0)

Articles

A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants

Aaron J. Schmitz, et al.

SARS-CoV-2 variants with increased transmissibility are a public health threat. Schmitz et al. characterize 2C08, a human monoclonal antibody derived from a SARS-CoV-2 vaccine-induced germinal center B cell. 2C08 possesses a broad and potent neutralization capacity and protects hamsters against challenge with D614G, B.1.351, or B.1.617.2 strains. Public 2C08-like clones can be elicited by both SARS-CoV-2 infection and vaccination.

Article / Online Now

mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants

Aurélien Sokal et al.

Published: September 20, 2021 DOI: <https://doi.org/10.1016/j.jimmuni.2021.09.011>

Highlights

- [1] Vaccination boosts high-affinity RBD-memory B cells (MBCs) in COVID-19 recovered patients
- [2] Boosted MBCs retain their diversity and express potent variant-neutralizing antibodies
- [3] SARS-CoV-2-naive individuals show low serum neutralization of variants after vaccination
- [4] Maturation of MBCs in naïve individuals allows them to respond to variants of concern

Summary

In addition to serum immunoglobulins, memory B cell (MBC) generation against SARS-CoV-2 represents another layer of immune protection, but the quality of MBC responses in naive and COVID-19-recovered individuals after vaccination remains ill-defined. We studied longitudinal cohorts of naive individuals and disease-recovered patients for up to 2 months after SARS-CoV-2 mRNA vaccination. We assessed the quality of the memory response by analysis of VDJ repertoires, affinity and neutralization against variants of concern (VOCs), using unbiased cultures of 2452 MBCs. Upon boosting, the MBC pool of recovered patients selectively expanded, further matured and harbored potent neutralizers against VOCs. Although naive individuals had weaker neutralizing serum responses, half of their RBD-specific MBCs displayed high affinity towards multiple VOCs, including delta (B.1.617.2), and one-third retained neutralizing potency against beta (B.1.351). Our data suggest that an additional challenge in naive vaccinees could recall such affinity-matured MBCs and allow them to respond efficiently to VOCs.

Infectious Agents and Cancer

<http://www.infectagentscancer.com/content>

[Accessed 2 Oct 2021]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>

[Accessed 2 Oct 2021]

[No new digest content identified]

International Health

Volume 13, Issue 5, September 2021

<https://academic.oup.com/inthealth/issue/13/5>

[Reviewed earlier]

International Human Rights Law Review

Volume 10 (2021): Issue 1 (Jun 2021)

<https://brill.com/view/journals/hrlr/10/1/hrlr.10.issue-1.xml>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 8, No 9 (2021) September 2021

<https://www.ijcmph.com/index.php/ijcmph/issue/view/80>

[Reviewed earlier]

International Journal of Epidemiology

Volume 50, Issue 4, August 2021

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 14 Issue 1 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/1>

Table of Contents

[Reviewed earlier]

International Journal of Infectious Diseases

August 2021 Volume 109 p1-324

<https://www.ijidonline.com/current>

[Reviewed earlier]

JAMA

September 28, 2021, Vol 326, No. 12, Pages 1133-1222

<https://jamanetwork.com/journals/jama/currentissue>

Research Letter

[Myocarditis and Pericarditis After Vaccination for COVID-19](#)

George A. Diaz, MD; Guilford T. Parsons, MD, MS; Sara K. Gering, BS, BSN; et al.

free access has active quiz

JAMA. 2021;326(12):1210-1212. doi:10.1001/jama.2021.13443

This study investigates the incidence of myocarditis and pericarditis emergency department or inpatient hospital encounters before COVID-19 vaccine availability (January 2019–January 2021) and during a COVID-19 vaccination period (February–May 2021) in a large US health care system.

Viewpoint

[COVID-19 in CanadaExperience and Response to Waves 2 and 3](#)

Allan S. Detsky, MD, PhD; Isaac I. Bogoch, MD, MS

free access has audio

JAMA. 2021;326(12):1145-1146. doi:10.1001/jama.2021.14797

This Viewpoint describes the Canadian experience and response to the larger second and third waves of COVID-19 infections.

Governing Human Germline Editing Through Patent Law

Jacob S. Sherkow, JD, MA; Eli Y. Adashi, MD, MS; I. Glenn Cohen, JD

JAMA. 2021;326(12):1149-1150. doi:10.1001/jama.2021.13824

This Viewpoint discusses ethical considerations and use of patents for human germline editing in the context of a recent World Health Organization report and release of several auxiliary documents exploring international governance tools for human genome engineering.

JAMA Network

COVID-19 Update October 2, 2021

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics

September 2021, Vol 175, No. 9, Pages 886-984

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBI Evidence Synthesis

September 2021 - Volume 19 - Issue 9

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

October 2021 Volume 69 Issue 4 p533-682

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 72 (2021)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 46, issue 5, October 2021

<https://link.springer.com/journal/10900/volumes-and-issues/46-5>

Correlates of HPV Vaccination Intentions Among Adults Ages 27–45 Years Old in the U.S.

Authors (first, second and last of 6)

Erika L. Thompson
Ashvita Garg
Christopher W. Wheldon
Content type: Original Paper
Published: 13 February 2021
Pages: 893 - 902

Factors Associated with Willingness to be Vaccinated Against COVID-19 in a Large Convenience Sample

Authors (first, second and last of 7)
Casey Dorman
Anthony Perera
Deborah DiazDeleon
Content type: Original Paper
Published: 09 April 2021
Pages: 1013 - 1019

Journal of Development Economics

Volume 152 September 2021
<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/152/suppl/C>
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 16 Issue 4, October 2021
<http://journals.sagepub.com/toc/jre/current>
[Reviewed earlier]

Journal of Epidemiology & Community Health

September 2021 - Volume 75 - 9
<https://jech.bmj.com/content/75/9>
[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 14, Issue 3 Pages: 171-256 September 2021
<https://onlinelibrary.wiley.com/toc/17565391/current>
[Reviewed earlier]

Journal of Global Ethics

Volume 11, Issue 1, 2021
<http://www.tandfonline.com/toc/rjge20/current>
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 32, Number 3, August 2021

<https://muse.jhu.edu/issue/45771>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 23, issue 5, October 2021

<https://link.springer.com/journal/10903/volumes-and-issues/23-5>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 19, 2021_ Issue 3

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 224, Issue 6, 15 September 2021

<https://academic.oup.com/jid/issue/224/6>

[Reviewed earlier]

Journal of Medical Ethics

September 2021 - Volume 47 - 9

<http://jme.bmjjournals.org/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 8, Issue 3 (2021)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

[Reviewed earlier]

Journal of Pediatrics

September 2021 Volume 236 p1-336

<http://www.jpeds.com/current>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 2 Oct 2021]

[Designing supply chains to meet the growing need of vaccines: evidence from four countries](#)

Immunization supply chains (iSCs) move vaccines from manufacturer to point of use with the added complexities of requiring cold chain and an increasing need for agility and efficiency to ensure vaccine quality...

Authors: Wendy Prosser, Cary Spisak, Benjamin Hatch, Joseph McCord, Marie Tien and Greg Roche

Citation: Journal of Pharmaceutical Policy and Practice 2021 14:80

Content type: Research

Published on: 29 September 2021

Impact of the first phase of COVID-19 pandemic on childhood routine immunisation services in Nepal: a qualitative study on the perspectives of service providers and users

The COVID-19 pandemic has disproportionately affected all essential healthcare services delivery in low-resource settings. This study aimed to explore the challenges and experiences of providers and users of c...

Authors: Asmita Priyadarshini Khatiwada, Smriti Maskey, Nistha Shrestha, Sunil Shrestha, Saval Khanal, Bhuvan KC and Vibhu Paudyal

Citation: Journal of Pharmaceutical Policy and Practice 2021 14:79

Content type: Research

Published on: 29 September 2021

Journal of Public Health Management & Practice

September/October 2021 - Volume 27 - Issue 5

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 42, issue 2, June 2021

<https://link.springer.com/journal/41271/volumes-and-issues/42-2>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

September 2021 Volume 18 Issue 182

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 28, Issue 6, August 2021

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 95 Number 19 September 2021

<http://jvi.asm.org/content/current> [Reviewed earlier]

The Lancet

Oct 02, 2021 Volume 398 Number 10307 p1195-1278, e15

<https://www.thelancet.com/journals/lancet/issue/current>

Articles

[Daily testing for contacts of individuals with SARS-CoV-2 infection and attendance and SARS-CoV-2 transmission in English secondary schools and colleges: an open-label, cluster-randomised trial](#)

Bernadette C Young, et al.

Daily contact testing of school-based contacts was non-inferior to self-isolation for control of COVID-19 transmission, with similar rates of symptomatic infections among students and staff with both approaches. Infection rates in school-based contacts were low, with very few school contacts testing positive. Daily contact testing should be considered for implementation as a safe alternative to home isolation following school-based exposures.

The Lancet Child & Adolescent Health

Oct 2021 Volume 5 Number 10 p681-766, e39-e43

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Sep 2021 Volume 3 Number 9 e534-e611

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Oct 2021 Volume 9 Number 10 e1336-e1473

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Sep 2021 Volume 21 Number 9 p1193-1332, e258-e301

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Sep 2021 Volume 6 Number 9 e620-e695

<https://www.thelancet.com/journals/lanpub/issue/current>
[Reviewed earlier]

Lancet Respiratory Medicine

Oct 2021 Volume 9 Number 10 p1077-1202, e96-e103

<https://www.thelancet.com/journals/lanres/issue/current>

Comment

[COVID-19 vaccines: addressing hesitancy in young people with allergies](#)

Elissa M Abrams, Marcus Shaker, Ian Sinha, Matthew Greenhawt

Articles

[Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial](#)

Tracy J Ruckwardt, get al; VRC 317 study team

Maternal and Child Health Journal

Volume 25, issue 10, October 2021

<https://link.springer.com/journal/10995/volumes-and-issues/25-10>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 41 Issue 7, October 2021

<http://mdm.sagepub.com/content/current>

Editorials

[The International Patient Decision Aid Standards \(IPDAS\) Collaboration: Evidence Update 2.0](#)

Dawn Stacey, Robert J. Volk, for the IPDAS Evidence Update Leads (Hilary Bekker, Karina Dahl Steffensen, Tammy C. Hoffmann, Kirsten McCaffery, Rachel Thompson, Richard Thomson, Lyndal Trevena, Trudy van der Weijden, and Holly Witteman)

First Published August 20, 2021; pp. 729–733

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 99, Issue 3 Pages: 601-852 September 2021

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Nature

Volume 597 Issue 7878, 30 September 2021

<https://www.nature.com/nature/volumes/597/issues/7878>

World View | 23 September 2021

[The incoming Afghan government must allow immunizations](#)

The world must work with Kabul's new rulers to get polio and other diseases under control.

Zulfiqar A. Bhutta

Nature Biotechnology

Volume 39 Issue 9, September 2021

<https://www.nature.com/nbt/volumes/39/issues/9>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 2 Oct 2021)

[No new digest content identified]

Nature Genetics

Volume 53 Issue 9, September 2021

<https://www.nature.com/ng/volumes/53/issues/9>

[Reviewed earlier]

Nature Human Behaviour

Volume 5 Issue 9, September 2021

<https://www.nature.com/nathumbehav/volumes/5/issues/9>

[Reviewed earlier]

Nature Medicine

Volume 27 Issue 9, September 2021

<https://www.nature.com/nm/volumes/27/issues/9>

[Reviewed earlier]

Nature Reviews Genetics

Volume 22 Issue 9, September 2021

<https://www.nature.com/nrg/volumes/22/issues/9>

[Reviewed earlier]

Nature Reviews Immunology

Volume 21 Issue 9, September 2021

<https://www.nature.com/nri/volumes/21/issues/9>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 20 Issue 9, September 2021

<https://www.nature.com/nrd/volumes/20/issues/9>

[Reviewed earlier]

New England Journal of Medicine

September 30, 2021 Vol. 385 No. 14

<http://www.nejm.org/toc/nejm/medical-journal>

Perspective

[Marking the 40th Anniversary of the AIDS Epidemic — American Physicians Look Back](#)

R. Bayer, G.M. Oppenheimer, and V. Parisi

Pediatrics

Vol. 148, Issue 3 1 Sep 2021

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

PharmacoEconomics

Volume 39, issue 9, September 2021

<https://link.springer.com/journal/40273/volumes-and-issues/39-9>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 2 Oct 2021)

Perspective

[Twenty steps to ingrain power asymmetry in global health biomedical research](#)

Iruka N. Okeke

| published 30 Sep 2021 PLOS Biology

<https://doi.org/10.1371/journal.pbio.3001411>

Health research in low-income settings must prioritize sustainability to truly impact target diseases in the long term. Here, I satirically summarize how biomedical investigators from high-income countries can collaboratively work to (not) accomplish this.

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 2 Oct 2021)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 2 Oct 2021)

[COVID-19 and global equity for health: The good, the bad, and the wicked](#)

Elvin H. Geng, Michael J. A. Reid, Eric Goosby, Quarraisha Abdool-Karim

Perspective | published 01 Oct 2021 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003797>

[Drought and child vaccination coverage in 22 countries in sub-Saharan Africa: A retrospective analysis of national survey data from 2011 to 2019](#)

Jason M. Nagata, Adrienne Epstein, Kyle T. Ganson, Tarik Benmarhnia, Sheri D. Weiser
Research Article | published 28 Sep 2021 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003678>

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 2 Oct 2021]

[Effect of a hospital-wide campaign on COVID-19 vaccination uptake among healthcare workers in the context of raised concerns for life-threatening side effects](#)

Min Hyung Kim, Nak-Hoon Son, Yoon Soo Park, Ju Hyun Lee, Da Ae Kim, Yong Chan Kim

Research Article | published 01 Oct 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0258236>

[Effects of political versus expert messaging on vaccination intentions of Trump voters](#)

Christopher T. Robertson, Keith Bentele, Beth Meyerson, Alex S. A. Wood, Jackie Salwa

Research Article | published 27 Sep 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0257988>

[Global research priorities for COVID-19 in maternal, reproductive and child health: Results of an international survey](#)

Melanie Etti, Jackeline Alger, Sofía P. Salas, Robin Sagers, Tanusha Ramdin, Margit Endler, Kristina Gemzell-Danielsson, Tobias Alfvén, Yusuf Ahmed, Allison Callejas, Deborah Eskenazi, Asma Khalil, Kirsty Le Doare, On behalf of the Maternal, Newborn and Child Health Working Group of the COVID-19 Clinical Research Coalition

Research Article | published 24 Sep 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0257516>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 2 Oct 2021]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

September 21, 2021; vol. 118 no. 38

<https://www.pnas.org/content/118/38>

Citizens from 13 countries share similar preferences for COVID-19 vaccine allocation priorities

Raymond Duch, Laurence S. J. Roope, Mara Violato, Matias Fuentes Becerra, Thomas S. Robinson, Jean-Francois Bonnefon, Jorge Friedman, Peter John Loewen, Pavan Mamidi, Alessia Melegaro, Mariana Blanco, Juan Vargas, Julia Seither, Paolo Candio, Ana Gibertoni Cruz, Xinyang Hua, Adrian Barnett, and Philip M. Clarke

PNAS September 21, 2021 118 (38) e2026382118; <https://doi.org/10.1073/pnas.2026382118>

Significance

How to allocate COVID-19 vaccines is one of the most important decisions currently facing governments. With limited supplies, what is most pressing is deciding who gets priority in the vaccine allocation rollout. Some governments are exploring allowing private purchases of COVID-19 vaccines. Many countries are debating whether COVID-19 vaccines should be mandated. There is little evidence on what policies are preferred by the global public. Our survey of 15,536 adults in 13 countries confirms that priority should be given to health workers and those at high risk but also, to a broad range of key workers and those with lower incomes. The public favors allocating COVID-19 vaccines solely via government programs but was polarized in some countries on mandatory vaccinations.

Abstract

How does the public want a COVID-19 vaccine to be allocated? We conducted a conjoint experiment asking 15,536 adults in 13 countries to evaluate 248,576 profiles of potential vaccine recipients who varied randomly on five attributes. Our sample includes diverse countries from all continents. The results suggest that in addition to giving priority to health workers and to those at high risk, the public favors giving priority to a broad range of key workers and to those with lower income. These preferences are similar across respondents of different education levels, incomes, and political ideologies, as well as across most surveyed countries. The public favored COVID-19 vaccines being allocated solely via government programs but were highly polarized in some developed countries on whether taking a vaccine should be mandatory. There is a consensus among the public on many aspects of COVID-19 vaccination, which needs to be taken into account when developing and communicating rollout strategies.

Prehospital & Disaster Medicine

Volume 36 - Issue 5 - October 2021

<https://www.cambridge.org/core/journalsprehospital-and-disaster-medicine/latest-issue>

[New issue; No digest content identified]

Preventive Medicine

Volume 150 September 2021

<https://www.sciencedirect.com/journal/preventive-medicine/vol/150/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

29 September 2021 Volume 288 Issue 1959

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 198 Pages e1-e34, 1-358 (September 2021)

<https://www.sciencedirect.com/journal/public-health/vol/198/suppl/C>

Research article Full text access

[Factors associated with COVID-19 vaccination intentions and attitudes in France](#)

M. Guillou, P. Kergall

Pages 200-207

Research article Abstract only

[The real-life impact of vaccination on COVID-19 mortality in Europe and Israel](#)

Katarzyna Jabłońska, Samuel Aballéa, Mondher Toumi

Pages 230-237

Research article Full text access

[Sociodemographic predictors of COVID-19 vaccine acceptance: a nationwide US-based survey study](#)

Pritish Mondal, Ankita Sinharoy, Lilly Su

Pages 252-259

Public Health Ethics

Volume 14, Issue 1, April 2021

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Reports

Volume 136 Issue 5, September/October 2021

<https://journals.sagepub.com/toc/phrg/136/5>

[Reviewed earlier]

Qualitative Health Research

Volume 31 Issue 10, August 2021

<https://journals.sagepub.com/toc/qhra/current>

[Reviewed earlier]

Research Ethics

Volume 17 Issue 4, October 2021

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 2 Oct 2021]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Selected Articles

29 Sep 2021

[Life expectancy, healthy life expectancy, and burden of disease in older people in the Americas, 1990–2019: a population-based study](#)

Original research | English |

29 Sep 2021

[Household structure of older persons in Latin America and the Caribbean](#)

Original research | Spanish |

28 Sep 2021

[Assessing health system responsiveness to the needs of older people](#)

Special report | English |

Risk Analysis

Volume 41, Issue 8 Pages: 1255-1495 August 2021

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 2 Oct 2021]

[No new digest content identified]

Science

Volume 374| Issue 6563| 1 Oct 2021

<https://www.science.org/toc/science/current>

[New issue; No digest content identified]

Science Translational Medicine

Volume 13| Issue 613| 29 Sep 2021

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Social Science & Medicine

Volume 284 September 2021

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/284/suppl/C>
[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>
[Accessed 2 Oct 2021]
[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 41, issue 5-6, December 2020
<https://link.springer.com/journal/11017/volumes-and-issues/41-5>
[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 43 September–October 2021
<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/43/suppl/C>
[Reviewed earlier]

Tropical Medicine & International Health

Volume 26, Issue 9 Pages: i-iv, 1015-1138 September 2021
<https://onlinelibrary.wiley.com/toc/13653156/current>
[Reviewed earlier]

Vaccine

Volume 39, Issue 39 Pages 5453-5726 (15 September 2021)
<https://www.sciencedirect.com/journal/vaccine/vol/39/issue/39>
Discussion Full text access

[Walking the Tightrope: Reevaluating science communication in the era of COVID-19 vaccines](#)

Matthew Z. Dudley, Roger Bernier, Janesse Brewer, Daniel A. Salmon
Pages 5453-5455

Research article Full text access

[Public attitudes toward COVID-19 vaccines on English-language Twitter: A sentiment analysis](#)

Siru Liu, Jialin Liu
Pages 5499-5505

Research article Open access

[Point-of-care vaccinators' perceptions of vaccine hesitancy drivers: A qualitative study from the cape metropolitan district, South Africa](#)

Elizabeth O. Oduwole, Hassan Mahomed, Christina A. Laurenzi, Heidi J. Larson, Charles S. Wiysonge
Pages 5506-5512

Research article Open access

[Continuity of routine immunization programs in Canada during the COVID-19 pandemic](#)

Hannah Sell, Ali Assi, S. Michelle Driedger, Ève Dubé, ... Shannon E. MacDonald

Pages 5532-5537

Research article Abstract only

[Influenza immunization coverage of children with sickle cell disease](#)

Hannah K. Peng, Kevin J. Dombkowski, Gary L. Freed, Susan E. Creary, ... Sarah L. Reeves

Pages 5538-5540

Volume 39, Issue 38 Pages 5333-5452 (7 September 2021)

<https://www.sciencedirect.com/journal/vaccine/vol/39/issue/38>

Discussion No access

[Children are the key to the Endgame: A case for routine pediatric COVID vaccination](#)

Mark R. Schleiss, Chandy C. John, Sallie R. Permar

Pages 5333-5336

Research article Abstract only

[Exploring socio-demographic and geospatial variation in human papillomavirus vaccination uptake in Virginia](#)

Jeanine N. Staples, Samhita L. Nelamangala, Sean Morris, Kristen Wells

Pages 5385-5390

Vaccines

<https://www.mdpi.com/journal/vaccines>

Open Access Review

[A Rapid Systematic Review of Factors Influencing COVID-19 Vaccination Uptake in Minority Ethnic Groups in the UK](#)

by Atiya Kamal, Ava Hodson and Julia M. Pearce

Vaccines 2021, 9(10), 1121; <https://doi.org/10.3390/vaccines9101121> (registering DOI) - 01 Oct 2021

Abstract

COVID-19 has disproportionately affected minority ethnic groups in the United Kingdom. To maximise the effectiveness of the vaccination programme, it is important to understand and address disparities in vaccine uptake. The aim of this review was to identify factors influencing COVID-19 vaccination uptake [...]

Open Access Article

[Women's Empowerment and Children's Complete Vaccination in the Democratic Republic of the Congo: A Cross-Sectional Analysis](#)

by Xinran Lu, Chuchu Fu, Qianyun Wang, Qiwei He, Jiayi He, Rie Takesue and Kun Tang

Vaccines 2021, 9(10), 1117; <https://doi.org/10.3390/vaccines9101117> (registering DOI) - 01 Oct 2021

Abstract

(1) Background: The empowerment of women contributes to better child health and wellness. This study aimed to examine the association between women's empowerment and complete vaccination of

children, as recommended in the National Expanded Program on Immunization (EPI) in the Democratic Republic of [...]

Open Access Article

Persuasive Messages Will Not Increase COVID-19 Vaccine Acceptance: Evidence from a Nationwide Online Experiment

by Raman Kachurka, Michał Krawczyk and Joanna Rachubik

Vaccines 2021, 9(10), 1113; <https://doi.org/10.3390/vaccines9101113> (registering DOI) - 30 Sep 2021

Abstract

Although mass vaccination is the best way out of the pandemic, the share of skeptics is substantial in most countries. Social campaigns can emphasize the many arguments that potentially increase acceptance for vaccines: e.g., that they have been developed, tested, and recommended by [...]

Open Access Article

Factors Associated with COVID-19 Vaccine Intentions in Eastern Zimbabwe: A Cross-Sectional Study

by Lauren McAbee, Oscar Tapera and Mufaro Kanyangarara

Vaccines 2021, 9(10), 1109; <https://doi.org/10.3390/vaccines9101109> (registering DOI) - 29 Sep 2021

Abstract

Vaccines are one of the most effective public health strategies to protect against infectious diseases, yet vaccine hesitancy has emerged as a global health threat. Understanding COVID-19 knowledge and attitudes and their association with vaccine intentions can help the targeting of strategies to [...]

Value in Health

September 2021 Volume 24 Issue 9 p1237-1390

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

.....

.....

medRxiv

medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 2 Oct 2021]

Selected Content

Actions for fostering cross-disciplinary global health research

Yan Ding, Ewan Tomeny, Imelda Bates, the IMPALA Consortium

medRxiv 2021.09.30.21264294; doi: <https://doi.org/10.1101/2021.09.30.21264294>

HPV vaccination of girls in the German model region Saarland: Insurance data-based analysis and identification of starting points for improving vaccination rates

Anna Marthaler, Barbara Berko-Goettel, Juergen Rissland, Jakob Schoepe, Emeline Taurian, Hanna Mueller, Gero Weber, Stefan Lohse, Thomas Lamberty, Bernd Holleczek, Harry Stoffel, Gunter Hauptmann, Martin Giesen, Christiane Firk, Alexandra Schanzenbach, Florian Brandt, Heike Hohmann, Quirin Werthner, Dominik Selzer, Thorsten Lehr, Stefan Wagenpfeil, Sigrun Smola
medRxiv 2021.10.01.21264397; doi: <https://doi.org/10.1101/2021.10.01.21264397>

Efficacy of COVID-19 vaccines in immunocompromised patients: A systematic review and meta-analysis

Ainsley Ryan Yan Bin Lee, Shi Yin Wong, Louis Yi Ann Chai, Soo Chin Lee, Matilda Lee, Mark Dhinesh Muthiah, Sen Hee Tay, Chong Boon Teo, Benjamin Kye Jyn Tan, Yiong Huak Chan, Raghav Sundar, Yu Yang Soon
medRxiv 2021.09.28.21264126; doi: <https://doi.org/10.1101/2021.09.28.21264126>

Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants

Katia Bruxvoort, Lina S. Sy, Lei Qian, Bradley K. Ackerson, Yi Luo, Gina S. Lee, Yun Tian, Ana Florea, Michael Aragones, Julia E. Tubert, Harpreet S. Takhar, Jennifer H. Ku, Yamuna D. Paila, Carla A. Talarico, Hung Fu Tseng
medRxiv 2021.09.29.21264199; doi: <https://doi.org/10.1101/2021.09.29.21264199>

Effectiveness of mRNA and ChAdOx1 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario

Sharifa Nasreen, Hannah Chung, Siyi He, Kevin A. Brown, Jonathan B. Gubbay, Sarah A Buchan, Deshayne B. Fell, Peter C. Austin, Kevin L Schwartz, Maria E. Sundaram, Andrew Calzavara, Branson Chen, Mina Tadrous, Kumanan Wilson, Sarah E. Wilson, Jeffrey C Kwong
medRxiv 2021.06.28.21259420; doi: <https://doi.org/10.1101/2021.06.28.21259420>

Improving older adults' vaccination uptake: are existing measures of vaccine hesitancy valid and reliable for older people?

Nicola Cogan, Allyson Gallant, Louise Nicholls, Susan Rasmussen, David Young, Lynn Williams
medRxiv 2021.09.29.21263161; doi: <https://doi.org/10.1101/2021.09.29.21263161>

Predictors of parents' intention to vaccinate their children against the COVID-19 in Greece: a cross-sectional study

Petros Galanis, Irene Vraka, Olga Siskou, Olympia Konstantakopoulou, Aglaia Katsiropoula, Ioannis Moisoglou, Daphne Kaitelidou
medRxiv 2021.09.27.21264183; doi: <https://doi.org/10.1101/2021.09.27.21264183>

* * * *

Think Tanks et al

Brookings [to 2 Oct 2021]
<http://www.brookings.edu/>

FixGov

For COVID-19 vaccinations, party affiliation matters more than race and ethnicity

William A. Galston
Friday, October 1, 2021

Center for Global Development [to 2 Oct 2021]

<http://www.cgdev.org/page/press-center>

Accessed 2 Oct 2021

[COVID-19 Vaccines: The Latest Airfinity Estimates](#)

Event 10/4/21

Airfinity is producing the most-referenced, real-time estimates of COVID-19 vaccine production, purchasing, stockpiling, expiry and delivery. As ministers of finance join the World Bank-IMF meetings this week, we discuss Airfinity's latest estimates showing a rapid upwards trend in production as well as a normalization of vaccine manufacturing and supply chains in the coming months; their work also highlights the extent of stockpiling by high-income country governments, the risks of massive wastage related to expiry dates, as well as the mismatch between vaccine delivery timelines and needs in countries with low vaccination rates and high case fatality rates.

Join us at CGD for a presentation and discussion with [Rasmus Hansen](#), CEO and Founder of Airfinity, on the key facts and issues for finance leaders related to vaccines as they consider priorities over the coming months.

[COVID-19 Stocktake and the Hurdles to Vaccine Access Across Africa](#)

Event 10/5/21

The COVID-19 pandemic has pushed up to 40 million Africans into extreme poverty and the continent experienced its first recession in half a century. Global vaccination efforts have left Africa behind: less than two percent of the African population has been vaccinated compared to over 70 percent in the European Union. As Delta and other emerging variants present new challenges for Africa, COVID-19 deaths have surged, hospital admissions have increased rapidly, and countries face shortages of oxygen and intensive care beds. During this high-level event, we will discuss the impact COVID-19 continues to have across Africa and the necessary measures the international community should take to address the emerging dangerous divergence between advanced and lower income economies. We hope to set the tone for conversations surrounding these challenging issues during the World Bank-IMF Annual Meetings.

Chatham House [to 2 Oct 2021]

<https://www.chathamhouse.org/>

Accessed 2 Oct 2021

[No new digest content identified]

CSIS

<https://www.csis.org/>

Accessed 2 Oct 2021

Critical Questions

[China Is Exploiting the Pandemic to Advance Its Interests, with Mixed Results](#)

September 30, 2021 | By [Bonny Lin](#), [Matthew P. Funaole](#), [Brian Hart](#), [Hannah Price](#)

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

October 1, 2021 *News Release*

The Decline in COVID-19 Deaths Among Nursing Home Residents and Staff Reversed Course Amid the Surging Delta Variant This Summer

The months-long decline in COVID-19 deaths among nursing home residents and staff reversed course this summer as the Delta variant dominated, with mortality increasing five-fold from 350 deaths in July to nearly 1,800 in August, finds a new KFF analysis. The analysis also finds increases in nursing home COVID-19 cases...

Rockefeller Foundation [to 2 Oct 2021]

<https://www.rockefellerfoundation.org/>

Selected Reports/Press Releases

Sep 23 2021

Press Releases

Pastors, Partners and Pop-ups: Report Shows Best Practices for Covid-19 Vaccination, Testing in Underserved Communities

Public health professionals in seven U.S. cities and states share how they increased vaccination and testing rates among their communities where rates were lowest New York | September 23, 2021 — ...

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

Copyright GE2P2 Global Foundation 2021. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::::

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable

development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the Bill & Melinda Gates Medical Research Institute , [PATH](#), and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *